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2,6-DISUBSTITUTED PIPERIDINES AND 
PIPERAZINE COMPOUNDS 
This application is a continuation-in-part of application 
Ser. No. 10/231,156 ?led Aug. 30, 2002, now US. Pat. No. 
6,943,177 Which in turn is a divisional of application Ser. 
No. 09/628,557 ?led Jul. 28, 2000, now US. Pat. No. 
6,455,543 B1, Which in turn claims priority under 35 U.S.C. 
§ 119(e)(1) to provisional Application No. 60/146,144 ?led 
Jul. 30, 1999, all of Which is incorporated herein by refer 
ence. 
FIELD OF INVENTION 
The present invention relates to lobeline analogs, i.e., 
2,6-disubstituted piperidine, and 2,6-disubstituted pipera 
Zine compounds, and their method of use in the treatment of 
diseases and pathologies of the central nervous system 
(CNS), the treatment of drug abuse and WithdraWal there 
from as Well as to the treatment of eating disorders such as 
obesity. The 2,6-disubstituted piperidine and piperaZine 
compounds of the present invention can be used for the 
treatment of drug abuse and WithdraWal therefrom, as Well 
as for the treatment of eating disorders such as obesity, and 
other neuropathologies. 
BACKGROUND OF THE INVENTION 
Alpha-Lobeline (lobeline), a lipophilic nonpyridino, alka 
loidal constituent of Indian tobacco, is a major alkaloid in a 
family of structurally-related compounds found in Lobelia 
in?ala. Lobeline has been reported to have many nicotine 
like effects, including tachycardia and hypertension (Olin et 
al., 1995), hyperalgesia (Hamann et al., 1994) and improve 
ment of learning and memory (Decker et al., 1993). Lobeline 
has high af?nity for nicotinic receptors (Lippiello et al., 
1986; Broussolle et al., 1989). HoWever, no obvious struc 
tural resemblance of lobeline to nicotine is apparent and 
structure function relationships betWeen S(—)-nicotine and 
lobeline do not suggest a common pharmacophore (BarloW 
et al., 1989). Also, differential effects of lobeline and nico 
tine suggest that these drugs may not be active through a 
common CNS mechanism, even though lobeline has been 
considered a mixed nicotinic agonist/antagonist. 
Lobeline evokes dopamine (DA) release from rat striatal 
slices. HoWever, lobeline evoked DA release is neither 
dependent upon extracellular calcium nor is it sensitive to 
mecamylamine, a noncompetitive nicotinic receptor antago 
nist. Thus, lobeline evoked DA release occurs via a different 
mechanism than does nicotine to evoke DA release (Teng et 
al., 1997, 1998; Clarke et al., 1996). In this respect, lobeline 
also inhibits DA uptake into rat striatal synaptic vesicles via 
an interaction With the dihydrotetrabenaZine (DTBZ) site on 
vesicular monoamine transporter-2 (V MAT2), thus increas 
ing the cytosolic DA available for reverse transport by the 
plasma membrane transporter (DAT) (Teng et al., 1997, 
1998). Thus, lobeline interacts With nicotinic receptors and 
blocks nicotine-evoked DA release, but also interacts With 
DA transporter proteins (DAT and VMAT2) to modify the 
concentration of DA in the cytosolic and vesicular storage 
pools, thereby altering subsequent dopaminergic neurotrans 
mission. 
Currently, drug discovery is focusing on neuronal nico 
tinic receptors (nAChRs) as novel targets for the develop 
ment of therapeutic agents for a Wide variety of central 
nervous system (CNS) diseases including, drug addiction, 
neuroendocrine, neuropsychiatric and neurological diseases, 
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memory and learning disabilities, eating disorders, and the 
control of pain, as Well as cardiovascular and gastrointesti 
nal disorders. Nicotinic receptor antagonists have good 
potential as therapeutic agents, since they offer another 
means of modulating nicotinic receptor function. Nicotinic 
agonists rapidly desensitiZe these receptors, essentially 
inhibiting their function. Thus, inhibition of nicotinic recep 
tor function may be the action, Which confers clinical utility, 
indicating that nicotinic receptor antagonists could also be 
bene?cial in the treatment of diseases for Which nicotinic 
agonists are currently being developed. For example, schiZo 
phrenia and drug abuse have both been associated With 
hyperactivity of CNS dopaminergic systems, and inhibition 
of nicotinic receptors may be advantageous in reducing such 
hyperactivity. Furthermore, the availability of subtype-se 
lective nicotinic receptor antagonists Will be invaluable 
agents in both basic and clinical research, With regard to 
both the treatment and diagnosis of disease. Finally, sub 
type-selective antagonists Will de?ne the role of speci?c 
nicotinic receptor subtypes in both physiological function 
and disease states. 
The action of many neuropharmacologically therapeutic 
agents involve the modulation of dopamine (DA), norepi 
nephrine (NE) and serotonin (5-HT) release, uptake and 
storage Within its respective terminals in the central nervous 
system (CNS). Most neurotransmitters are stored in synaptic 
vesicles, Which are prominent features of nerve terminals. 
Concentration into vesicles appears to be responsible for 
maintaining a ready supply of neurotransmitter available for 
neuronal exocytotic release into the synaptic cleft. Vesicles 
also serve the role of protecting the neurotransmitter from 
metabolic breakdown. One transport site on the vesicle 
membrane is the vesicular monoamine transporter-2 
(V MAT2), Whose role is to transport transmitter from the 
cytosol into the synaptic vesicle. DihydrotetrabenaZine 
(DTBZ), a ligand structurally related to methoxytetrabena 
Zine (MTBZ), has been used as a radiolabel to probe the 
interaction of drugs With VMAT2. Both DTBZ and MTBZ 
act at the same site on VMAT2. Once the neurotransmitter 
is released from the terminal into the synaptic space, it 
interacts With postsynaptic receptors and subsequently is 
taken back up into the terminal via the plasma membrane 
transporter (e.g., the dopamine transporter [DAT] and/or the 
serotonin transporter [SERT]). Thus, transporter proteins 
modify the concentration of neurotransmitter in the cytosolic 
and vesicular storage pools, thereby having the ability to 
alter subsequent neurotransmission. 
SUMMARY OF THE INVENTION 
The present invention is directed to a method of treating 
an individual Who suffers from an eating disorder, from a 
disease or pathology of the central nervous system (CNS) or 
for treating an individual for drug dependence or WithdraWal 
for drug dependence. The method comprises the step of 
administering to the individual an effective amount of a 
2,6-disubstituted piperidine or piperaZine lobeline analog, 
including pharmaceutically acceptable salts of such com 
pounds thereof. As used herein, an “effective amount” refers 
to an amount of a drug effective to reduce an individual’s 
desire for a drug of abuse or for food, or for alleviating at 
least one of the symptoms of the disease or pathological 
symptom of a CNS pathology. 
The compound can be administered alone, combined With 
an excipient, or co-administered With a second drug having 
a similar or synergistic effect. The compound is adminis 
tered subcutaneously, intramuscularly, intravenously, trans 
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dermally, orally, intranasally, intrapulmonary or rectally. 
The 2,6-disubstituted piperdine and piperaZine analogs 
thereof in treating diseases or pathologies of the CNS is 
implicated. In particular, the treatment of dependencies on 
such drugs as cocaine, amphetamines, caffeine, nicotine, 
phencyclidine, opiates, barbiturates, benZodiaZepines, can 
nabinoids, hallucinogens, and alcohol is implicated. Also, 
the treatment of eating disorders such as obesity is impli 
cated. 
In a preferred aspect of the invention, the method of 
treatment reduces an individual’s desire for the drug of 
abuse or for food by at least one day, but it is also preferred 
that the treatment method further comprises administering 
behavior modi?cation counseling to the individual. 
Although the compound of the present invention is contem 
plated primarily for the treatment of drug abuse and With 
draWal and for eating disorders, other uses are also sug 
gested by the studies discussed herein. Thus, cognitive 
disorders, brain trauma, memory loss, psychosis, sleep dis 
orders, obsessive compulsive disorders, panic disorders, 
myasthenia gravis, Parkinson’s disease, AlZheimer’s dis 
ease, schizophrenia, Tourette’s syndrome, Huntington’s dis 
ease, attention de?cit disorder, hyperkinetic syndrome, 
chronic nervous exhaustion, narcolepsy, pain, motion sick 
ness and depression, and related conditions are considered to 
be susceptible to treatment With a compound of the present 
invention. 
As shoWn by the results of the studies described herein, 
lobeline analogs are found to be effective in inhibiting 
uptake of extracellular DA by cells of the CNS. Some of 
these analogs are also nicotinic receptor antagonists. Either 
or both mechanisms can thereby Work to alter the distribu 
tion of the intracellular DA pools and as a result alter 
extracellular DA concentration. 
Further as shoWn by the results of the studies described 
herein, the 2,6-disubstituted piperidine analogs are found to 
be effective in inhibiting uptake of extracellular 5-HT by 
serotonergic nerve terminals in the CNS, as Well as in 
inhibiting the binding of [3 H] MTBZ or [3 H] DTBZ to vesicle 
membranes indicating an interaction With VMAT2. These 
analogs are also nicotinic receptor antagonists, inhibiting 
nicotine-evoked [3H]DA and [3H]NE release from rat brain 
slices. Either or both mechanisms can thereby alter the 
distribution of the intracellular neurotransmitter pools, and 
as a result, alter extracellular neurotransmitter concentra 
tions. 
As used herein the term “lobeline” refers to a compound 
having the general chemical formula 2-[6-([3-hydroxyphen 
ethyl)- l -methyl-2 -piperidyl] -acetophenone. The term 
“lobeline analogs” and equivalents thereof as used herein, 
refers to chemical derivatives of lobeline obtained by oxi 
dation or reduction of lobeline, others obtained by esteri? 
cation of lobeline and redox derivatives, as Well as various 
substitutions at the N-position of the piperidinyl moiety, 
different substituents at the piperidinyl C2 and C6 positions, 
compounds With different combinations of chiralities at 
positions 2 and 6 on the piperidinyl ring, aZa analogs at the 
C4 position of the piperidinyl ring, a variety of aryl moieties 
replacing the tWo phenyl moieties, and a variety of substitu 
ents in one or more of the aryl moieties. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The 2,6-disubstituted piperidine and piperaZine analogs of 
the present invention include those contemplated by the 
folloWing formula (I), Without regard to chirality: 
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(1) 
R4 
Z 
31K Di Yi ,Yl R3/ ‘x2 N X" \R2 
1L1 
Wherein: 
n is Zero or an integer in the range from 1 to 3; 
XliYl and XZiY2 are the same or are independently 
different from one another and represent a saturated carbon 
carbon bond, a cis-carbon-carbon double bond, a trans 
carbon-carbon double bond, a carbon-carbon triple bond; a 
saturated sulfur-carbon bond, a saturated selenium-carbon 
bond, an oxygen-carbon bond, a saturated nitrogen-carbon 
bond, a N-alkyl substituted saturated nitrogen-carbon bond 
Where said alkyl is a loWer straight chain or branched alkyl, 
a nitrogen-carbon double bond, or a nitrogen-nitrogen 
double bond; 
Z-R4 represents NiR4, CHiR4 or C=O, Where R4 is 
hydrogen or a loWer straight chain or branched alkyl; 
R1 represent hydrogen or a loWer straight chain or 
branched alkyl, cycloalkyl, vinyl, allyl, alkenyl (including 
cis and trans geometrical forms), benZyl, and phenylethyl, 
or, When Z is CHiR4, R1 and R4 together form a ring 
including a iCHZi, 4OiCH2iOi, 4CH2CH2i, 
%H2CH2iCH2i, -cis-CH=CH, -cis-CH2i 
CH=CHi or -cis-CH2=CHiCH2i moiety; and 
R2 and R3 are the same or are independently different from 
one another and represent a saturated or unsaturated hydro 
carbon ring; a nitrogen containing heterocyclic moiety; an 
oxygen containing heterocyclic moiety; a sulfur containing 
heterocyclic moiety; a selenium containing heterocyclic 
moiety; a mixed heterocyclic moiety containing at least tWo 
atoms selected from the group consisting of nitrogen, oxy 
gen and sulfur; and an ortho, meta or para-substituted 
benZene. 
The substituted benZene of formula (I) is a substituted 
phenyl Wherein the substituent moiety is a methyl, ethyl, 
propyl, isopropyl, butyl, sec-butyl isobutyl, C5-C7 straight 
chain or branched alkyl, C3-C6 cycloalkyl, C4-C7 alkenyl 
(including cis and trans geometrical forms), benZyl, and 
phenylethyl. Further, the substitute moieties can be amino, 
N-methylamino, N,N-dimethylamino, carboxylate, methyl 
carboxylate, ethylcarboxylate, propylcarboxylate, isopropy 
lcarboxylate, carboxaldehyde, acetoxy, propionyloxy, iso 
propionyloxy, cyano, aminomethyl, N-methylaminomethyl, 
N,N-dimethylaminomethyl, carboxamide, N-methylcar 
boxamide, N,N-dimethylcarboxamide, acetyl, propionyl, 
formyl, benZoyl sulfate, phenyl, methylsulfate, hydroxyl, 
methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, 
ethylthio, propiothiol, ?uoro, chloro, bromo, iodo, tri?uo 
romethyl, vinyl, allyl, propargyl, nitro, carbamoyl, ureido, 
aZido, isocyanate, thioisocyanate, hydroxylamino and 
nitroso. 
It is preferred that When either XliYl or XZiY2 is a 
saturated carbon-carbon bond, Y1 or Y2 represents CH2, 
CH4OH, CHO-alkyl Where said alkyl is a loWer straight 
chain or branched alkyl, CH4OSO24C6H5, CH4OSO2 
p-C6H4CH3, CHiSH, C6H5iSH, CHiS-alkyl Where said 
alkyl is a loWer straight chain or branched alkyl, CHiNOz, 
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CH4CF3, CHiNHOH, CHiOCHO, CHiF, CH4Cl, 
CHiBr, CHiI, CHiNHz, CHiNH-alkyl Where said 
alkyl is a lower straight chain or branched alkyl, CHiN 
(alkyl)2 Where said alkyl is a lower straight chain or 
branched alkyl, CH4OCONH2, CHiOCONH-alkyl 
Where said alkyl is a loWer straight chain or branched alkyl, 
CH4OCON(alkyl)2 Where said alkyl is a loWer straight 
chain or branched alkyl, CHiN3, C=O or C=S; CHiO 
aryl such as a phenyl, ortho-, meta-, or para-substituted 
phenyl Where the substituent is as described above; or a 
hydrocarbon or hetercyclic ring such as pyridyl, furanyl, 
naphthyl, thiaZole, selenothenyl, oXaZolyl, 1,2,3-triazole, 
1,2,4-triazole, imidaZoline, pyrimidine, pyridaZine or triaZ 
ine, including all possible substitution patterns, diastereo 
meric and enantiomeric forms thereof. 
The loWer straight or branched alkyl can be an alkyl group 
containing one to seven carbon atoms, With methyl and ethyl 
being preferred. Rl represents a hydrogen, methyl, deuter 
omethyl (CD3), tritiomethyl (CT3), ethyl, or C3-C7 straight 
chain or branched alkyl (preferably methyl or ethyl), C3-C6 
cycloalkyl, vinyl, allyl, C4-C7 alkenyl (including cis and 
trans geometrical forms), benZyl, and phenylethyl. 
The above 2,6-substituted piperidino or piperaZino ana 
logs are preferred in their cis-geometrical isomeric forms, or 
in their trans geometric forms, including all possible geo 
metric, racemic, diasteriomeric, and enantiomeric forms 
thereof. 
The above 2,6-disubstituted piperidines or piperaZines as 
Well as analogs thereof can be administered in their free base 
form or as a soluble salt. Whenever it is desired to employ 
a salt of a 2,6-substituted piperidine or its analog, it is 
preferred that a soluble salt be employed. Some preferred 
salts include hydrochloride, hydrobromide, nitrate, sulfate, 
phosphate, tartrate, galactarate, fumarate, citrate, maleate, 
glycolate, malate, ascorbate, lactate, aspartate, glutamate, 
methanesulfonate, p-toluenesulfonate, benZenesulfonate, 
salicylate, proprionate, and succinate salts. The above salt 
forms may be in some cases hydrates or solvates With 
alcohols and other solvents. 
In one embodiment, When n:0, R2 and R3 are unsubsti 
tuted phenyl groups, and XliYl and XZiY2 are saturated 
carbon-carbon bonds, Yl cannot be CH2, CHOH or C=O, 
and Y2 cannot be CH2, CHOH, or C=O. 
In another embodiment, When R2 and/ or R3 is a saturated 
hydrocarbon ring, the ring includes, but is not limited to, 
cyclobutane, cyclopentane, cyclohexane, cycloheptane or 
cyclooctane, including all possible substitution patterns, 
geometric and stereoisomers, racemic, diastereomeric and 
enantiomeric forms thereof. 
In still a further embodiment, When R2 and/or R3 is an 
unsaturated hydrocarbon ring, the ring includes, but is not 
limited to, benZene, cyclopentene, cyclohexene, cyclohep 
tene, cyclooctene, cyclopentadiene, or napthylene, including 
all possible substitution patterns, geometric and stereoiso 
mers, racemic, diastereomeric and enantiomeric forms 
thereof. 
In still another embodiment, When R2 and/or R3 is a 
nitrogen containing heterocyclic moiety, the moiety 
includes, but is not limited to, aZetine, piperidine, pipera 
Zine, pyraZine, pyraZole, pyraZolidine, imidaZole imidaZo 
line, pyrimidine, hexa-hydropyrimidine, pyrrole, pyrroli 
dine, triaZine, 1,2,3-triazole, 1,2,4-triazole, pyridine or 
pyridaZine, including all possible substitution patterns, geo 
metric and stereoisomers, racemic, diastereomeric and enan 
tiomeric forms thereof. 
In still a further embodiment, When R2 and/or R3 is an 
oxygen containing heterocyclic moiety, the moiety includes, 
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6 
but is not limited to, furan, tetrahydrofuran, 2,5-dihydrofu 
ran, pyran, tetrahydropyran, l,4-dioxane, 1,3-dioxane or 
1,4-oxathinin, including all possible substitution patterns, 
geometric and stereoisomers, racemic, diastereomeric and 
enantiomeric forms thereof. 
In still a further embodiment, When R2 and/or R3 is a 
sulfur containing heterocyclic moiety, the moiety includes, 
but is not limited to, thietane, thiophene, thiophane, 2,5 
dihydrothiophene, 1,3-dithiolylium, 1,3-dithiolane, 1,2 
dithiolylium, 1,2-dithiolane, thiane, 1,2-dithiane, 1,3-dith 
ane, l,4-dithiane, or thiopyranylium, including all possible 
substitution patterns, geometric and stereoisomers, racemic, 
diastereomeric and enantiomeric forms thereof. 
In still a further embodiment, When R2 and/or R3 is a 
selenium containing heterocyclic moiety, the moiety 
includes, but is not limited to, selenophene, including all 
possible substitution patterns, geometric and stereoisomers, 
racemic, diastereomeric and enantiomeric forms thereof. 
In still a further embodiment, When R2 and/or R3 is a 
mixed heterocyclic moiety, the moiety includes, but is not 
limited to, thiaZolidine, thiaZole and oxaZin, including all 
possible substitution patterns, geometric and stereoisomers, 
racemic, diastereomeric and enantiomeric forms thereof. 
Still another embodiment is a 2,6-disubstituted piperdine 
analog having the folloWing formula (II): 
(11) 
/ 
R5 
Wherein 
R5 represents a hydrogen, methyl, deuteromethyl (CD3), 
tritiomethyl (CT3), ethyl, or C3-C7 straight chain or 
branched alkyl (preferably methyl or ethyl), C3-C6 
cycloalkyl, vinyl, allyl, C4-C7 alkenyl (including cis and 
trans geometrical forms), benZyl, and phenylethyl; and 
R6 and R7 are substituted phenyls, each independently 
ortho-, meta-, or para-substituted moieties, Where the sub 
stituent is described as hydrogen, methyl, ethyl, or C3-C7 
straight chain or branched alkyl, C3-C6 cycloalkyl, vinyl, 
allyl, C4-C7 alkenyl (including cis and trans geometrical 
forms), benZyl, and phenylethyl. Further, the substitute 
moieties can be N-methylamino, N,N-dimethylamino, car 
boxylate, methylcarboxylate, ethylcarboxylate, propylcar 
boxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, 
propionyloxy, isopropionyloxy, cyano, aminomethyl, N-me 
thylaminomethyl, N,N-dimethylaminomethyl, carboxam 
ide, N-methylcarboxamide, N,N-dimethylcarboxamide, 
acetyl, propionyl, formyl, benZoyl, sulfate, methylsulfate, 
hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, 
methylthio, ethylthio, propiothiol, ?uoro, chloro, bromo, 
iodo, tri?uoromethyl, propargyl, nitro, carbamoyl, ureido, 
aZido, isocyanate, thioisocyanate, hydroxylamino, and 
nitroso. 
The above 2,6-substituted piperidino analogs for formulas 
(I) and (II) are preferred in their 2,6-cis geometrical isomeric 
forms, or in their 2,6-trans geometric forms, including all 
possible geometric, racemic, diasteriomeric, and enantio 
meric forms thereof. 
A pharmaceutical composition containing a compound of 
the invention is also contemplated, Which may include a 
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conventional additive, such as a stabilizer, bulfer, salt, 
preservative, ?ller, ?avor enhancer and the like, as knoWn to 
those skilled in the art. Representative bulfers include phos 
phates, carbonates, citrates and the like. Exemplary preser 
vatives include EDTA, EGTA, BHA, BHT and the like. A 
composition of the invention may be administered by inha 
lation, i.e., intranasally as an aerosol or nasal formulation; 
topically, i.e., in the form of an ointment, cream or lotion; 
orally, i.e., in solid or liquid form (tablet, gel cap, time 
release capsule, poWder, solution, or suspension in aqueous 
or non aqueous liquid; intravenously as an infusion or 
injection, i.e., as a solution, suspension or emulsion in a 
pharmaceutically acceptable carrier; transdermally, e.g., via 
a transdermal patch; rectally as a suppository and the like. 
Generally, the pharmacologically effective dose of a 
present compound is in the amount ranging from about 
l><l0 to about 1 mg/kg body Weight/day. The amount to be 
administered depends to some extent on the lipophilicity of 
the speci?c compound selected, since it is expected that this 
property of the compound Will cause it to partition into fat 
deposits of the subject. The precise amount to be adminis 
tered can be determined by the skilled practitioner in vieW 
of desired dosages, side effects and medical history of the 
patient and the like. 
The 2,6-disubstituted piperidino and piperaZino analogs 
of the present invention exhibit selectivity for either neu 
ronal nicotinic acetylcholine receptors (nAChRs) and/ or the 
dopamine transporter protein (DAT) and/or the serotonin 
transporter protein (SERT) and/or the norepinephrine trans 
porter (NET) and/or the vesicular monoamine transporter 
(VMAT2). 
(111) 
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TABLE 1 -continued 
Inhibition of Inhibition of 
Inhibition of Nicotine- Nicotine 
Nicotine- Evoked[3H] Evoked[3H] 
[3H]Nicotine [3H]MLA Evoked DA NE [3H]5-HT Inhibition of 
Binding Binding 86Rb+ Ef?ux“ Overflowb [3H]DA Overflowb Uptake [3H]DTBZ 
(Ki) (Ki) (IC5O) (1C 50) Uptake (IC5O) (Ki) binding (Ki) 
0L4[52* (17* 0L4[52* 0L6[52* (1364* SERT VMAT2 
Compd (um) (um) (um) (um) (um) (um) (um) (um) 
47 ND ND ND ND ND ND ND ND 
48 >100 >100 ND ND ND ND ND 5.20 
49 >100 >100 ND ND ND ND ND 5.10 
50 >100 >100 ND ND ND ND ND ND 
51 >100 >100 ND ND ND ND ND 1.07 
52 >100 >100 ND ND ND ND ND ND 
53 >100 >100 ND ND ND ND ND ND 
54 ND ND ND ND ND ND ND ND 
55 ND ND ND ND ND ND ND ND 
56 ND ND ND ND ND ND ND ND 
57 ND ND ND ND ND ND ND ND 
58 ND ND ND ND ND ND ND ND 
59 ND ND ND ND ND ND ND ND 
ND: not determined 
NI: no inhibition 
aInhibition of1 [1M S(—)—nicotine 
bInhibition of 10 [1M S(—)—nicotine 
CData of a mixture of compound 10 and 11 
The invention will now be discussed by certain examples 
that illustrate but do not limit the invention. Table 2 below 
summarizes the inhibition of methamphetamine-evoked 
endogenous DA release from striatal slices. 
TABLE 2 
Inhibition of Methamphetamine 
Evoked DA Over?ow 
1050 01M) 
Compd (Mean) 
1 1 .25 
14 0.70 
15 >100 
16 0.43 
17 0.44 
1 8 >100 
19 >100 
The 2,6-disubstituted piperidino and 2,6-disubstituted 
piperaZino analogs listed in Table 1 have the chemical 
structure of formula (III). They were assayed for nicotinic 
receptor interaction ((>t4[32* and (>t6[32* and (>t3[34*; how 
ever, the * indicates the putative nature of the nicotinic 
receptors and does not limit the invention to other putative 
nicotinic receptor subtypes of native composition) and inhi 
bition of dopamine transporter protein (DAT), the serotonin 
transporter (SERT), the norepinephrine transporter (NET), 
and the vesicular monoamine transporter (VMAT2) activity. 
Selected compounds in Table 1 were evaluated in the high 
af?nity [3H]nicotine binding assay and afforded inhibition 
constants (Ki values) ranging from 0.011 uM to greater than 
100 nM. Three of these compounds were in the range of 
11-440 nM. Ten compounds were in the range of 05-77 uM. 
Many compounds had Ki values greater than 100 nM. 
Selected compounds in Table 1 were evaluated in the 
86Rb+ ef?ux assay using rat thalamic synapotosomes. This 
functional assay assesses the interaction of the compounds 
with the nicotinic receptor subtype probed by the [3 H] 
nicotine binding assay and provides an initial indication if 
the compound acts as an agonist, partial agonist or antago 
30 
35 
40 
45 
nist at this receptor subtype. The compounds with the 
highest af?nity in the [3H]nicotine binding assay were 
evaluated in the functional 86Rb+ e?lux assay and were 
shown to be potent inhibitors of nicotine-evoked 86Rb+ 
el?ux. IC5O values were in the range 0.002 EM-0.73 tM. 
Thus, these compounds appear to act as nicotinic receptor 
antagonists. 
Compounds in Table 1 were evaluated for their ability to 
inhibit [3H]methyllycaconitine ([3H]MLA) binding to rat 
whole brain membranes to assess potential interaction with 
the 0t7* nicotinic receptor sites. Some of the compounds 
show low af?nity with a range of Ki values of 1.25 uM-55 
uM. Many of the compounds exhibited Ki values greater 
than 100 uM at this nicotinic receptor subtype. 
Compounds in Table 1 were evaluated for their ability to 
evoke or inhibit nicotine-induced [3H]dopamine ([3H]DA) 
or nicotine-induced [3H]norepinephrine ([3H]NE) release 
from superfused rat striatal and hippocampal slices in vitro 
to assess interaction with (>t6[32* and (1364* nicotinic recep 
tors, respectively (again, the * indicates the putative desig 
nation for the subunit composition of these nicotinic recep 
tor subtypes and does not limit the invention to other subunit 
compositions for the nicotinic receptors). Two compounds 
(compounds 14 and 18) exhibited very potent inhibition if 
nicotine-evoked [3H]DA over?ow (IC5O:0.3 and 3.0 nM). 
Four compounds (compounds 1, 2, 15 and 25) exhibited 
inhibition with IC 50 values in the range 0.1-1.0 uM. Several 
compounds showed no inhibition of the (>t6[32* nicotinic 
receptor (nicotinic receptor mediating nicotine-evoked [3H] 
DA release from striatum). With respect to compounds 
inhibiting nicotine-evoked [3H]NE over?ow from hippoc 
ampus, several compounds exhibited IC50 values from 
0.01-0.03 uM, showing inhibition at 06 [34* nicotinic recep 
tors. 
The 2,6-disubstituted piperidino and 2,6-disubstituted 
piperaZino analogs listed in Table 1 were also assayed for 
inhibition of DAT activity, i.e., inhibition of [3H]DA uptake 
into the dopaminergic presynaptic terminal. Eleven com 
pounds were evaluated and afforded inhibition constants (Ki 
values) ranging from 0.26 uM to 33 nM. Removal of both 
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functionalities of the lobeline molecule resulted in loss of 
af?nity for the nicotinic receptor probed by [3H]nicotine 
binding and a 15-100-fold more potent inhibition of the 
dopamine transporter (DAT) compared With lobeline. 
Removal of either the hydroxyl group or the keto group of 
lobeline resulted in a 50-fold loss of af?nity for the nicotinic 
receptor. Interestingly, the ketoalkene analog inhibited DAT 
17-fold more potently than lobeline, Whereas lobelanidine 
inhibited DAT equipotently compared to lobeline. Conver 
sion of the hydroxy group of lobeline to a bulky tosyloxy 
group did not alter the af?nity at nicotinic receptors probed 
by [3H]nicotine binding, and did not alter the interaction 
With the DA transporter. Trans-meso-transdiene (Compound 
15) Was the most potent compound in the DA uptake assay, 
but had 1000-fold loWer af?nity for the nicotinic receptor 
compared to lobeline. This data indicates that appropriate 
structural modi?cation of the lobeline molecule alfords 
compounds in Which the interaction With DAT is enhanced. 
Furthermore, in one compound, i.e., meso-transdiene (Com 
pound 14), the nicotinic receptor interaction has been elimi 
nated and the compound is relatively selective for inhibition 
of DAT. 
The 2,6-disubstituted piperidino and 2,6-disubstituted 
piperaZino analogs of the present invention exhibited activ 
ity at the serotonin transporter (SERT). Three compounds 
(compounds 6, 10 and 15) exhibited inhibition of serotonin 
uptake With Ki values ranging from 0.01 uM-0.38 11M. A 
number of compounds exhibited Ki values in the range of 
1.6 11M -26 nM. 
The 2,6-disubstituted piperidino and 2,6-disubstituted 
piperaZino analogs of the present invention exhibited activ 
ity at the vesicular monoamine transporter (VMAT2). Five 
compounds (compounds 17, 33, 35, 37, 39) exhibited inhi 
bition of [3H]DTBZ binding With Ki values in the range 0.43 
uM-0.68 11M. A number of compounds exhibited Ki values 
in the range of 1.1 uM-18.5 11M. 
The 2,6-disubstituted piperidino analogs of the present 
invention inhibited methamphetamine-evoked endogenous 
DA over?oW from superfused rat striatal slices. Four com 
pounds (compounds 1, 14, 16, and 17) exhibited lC50 values 
in the range 0.43 uM-1.25 11M. Compounds 15, 18 and 19 
exhibited lC50 values greater than 100 11M. 
Tables 3 beloW summarizes data from an earlier study of 
2,6-disubstituted piperidino analogs of the present invention 
shoWing that they exhibit selectivity for either nAChRs 
and/or DAT. The previous data also shoWs that the analogs 
active toWards the nicotinic receptor generally do not inter 
act With the DAT, and those that interact With the DAT shoW 
only modest nicotinic receptor activity. The nine 2,6-disub 
stituted piperidino analogs listed in Table 3 have the chemi 
cal structure of formula (IV). 
TABLE 3 
(W) 
Y% ,Yl \XZ“ If "IXI. 
CH3 
Ki (PM) Ki (PM) 
[3H]-Nicotine [3H]-Dopalnine 
Compound Binding Assay Uptake Assay 
0.0043 45 
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TABLE 3-continued 
(IV) 
Y1 “X1 
‘X2 N ”x1 
A... 
Ki (11M) Ki (11M) [3H]-Nicotine [3H]-Doparnine 
Compound Binding Assay Uptake Assay 
17. X1= X2 = Y1= Y2 = cH2 14.3 3.0 
2. X1= X2 = cH2 0.0041 39 
Y1 = c:o 
Y2 = (S)iCHOSO24C6H4—p—CH3 
3. X1=X2=CH2 11 25 
Y1 = Y2 = c:o 
14. X1,Y1 = X2,Y2 = trans CHICH >100 0.8 
5. X1=CH2 0.13 3.0 
Y1 = c:o 
X2,Y2 = trans CHICH 
4. X1 = X2 = cH2 0.93 54 
Y1 = (S)iCHOH 
Y2 = (10411011 
60. X1=X2 =Y2 =cH2 0.16 8.9 
Y1 = (RS)4CHOH 
7. X1= cH2 4.2 1.3 
Y1 = (S)iCHOH 
X2,Y2 = trans CHICH 
Compound 60 is a mixture of epimers from the earlier study. 
The mixture Was subsequently separated providing the indi 
vidual epimers, compounds 10 and 11 in Table 1. 
The nine compounds in Table 3 Were evaluated in the high 
af?nity [3H]nicotine binding assay and afforded inhibition 
constants (Ki values) ranging from 0.0043 11M to >100 11M. 
Five of these compounds had Ki values in the range of 4-160 
nM. Three of these compounds had Ki values in the range of 
0.93-14 11M. The cis-2,6-disubstituted piperidino analogs 
listed in Table 3 Were also assayed for inhibition of DAT 
activity, i.e., inhibition of [3H]DA uptake into the dopam 
inergic presynaptic terminal. Nine compounds in Table 3 
Were evaluated and afforded inhibition constants (Ki values) 
ranging from 0.08 11M to 54 11M. 
Removal of both functionalities of the lobeline molecule 
resulted in loss of affinity for the nicotinic receptor and a 
100-fold more potent inhibition of the dopamine transporter 
(DAT) compared With lobeline. Removal of either the 
hydroxyl group or the keto group of lobeline resulted in a 
50-fold loss of af?nity for the nicotinic receptor. Interest 
ingly, the ketoalkene analog inhibited DAT 10-fold more 
potently than lobeline, Whereas lobelanidine inhibited DAT 
equipotently compared to lobeline. Conversion of the 
hydroxy group of lobeline to a bulky tosyloxy group reduced 
the af?nity of the nicotinic receptor by only 3-fold, but did 
not alter the interaction With the DA transporter. The 
hydroxyalkene had a similar potency With the meso-trans 
diene (the most potent compound) in the DA uptake assay, 
but had 1000-fold loWer af?nity for the nicotinic receptor. 
Also, the completely defunctionaliZed lobeline molecule and 
the hydroxyalkane analog Were both less potent than the 
meso-transdiene in inhibiting DA uptake into striatal syn 
aptosomes. This data indicates that appropriate structural 
modi?cation of the lobeline molecule affords compounds in 
Which the interaction With DAT is enhanced. Furthermore, in 
one compound, i.e., the meso-transdiene, the nicotinic 
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receptor interaction has been eliminated and the compound 
is thus selective for inhibition of DAT. 
Earlier studies of the 2,6-disubstituted piperidino analog 
Compounds 14 and 15 shoW that the compounds exhibit 
activity at either nAChRs and/or the serotonin transporter 
protein (SERT) and/ or the vesicular monoamine transporter 
(VMAT2). 
Compound 14 
Cis-Z,6-di-trans-styrylpiperidine 
C113 
C113 
Compound 15 
Trans-2,6-di-trans-styrylpiperidine 
Table 4 beloW summarizes the data from the earlier 
studies showing interaction of Compound 14 and Com 
pound 15 With nicotinic receptors, SERT and VMAT2. 
5 
10 
16 
vesicle membranes and inhibition of SERT function. Com 
pound 15 exhibits good selectivity (9.5-fold) for the 0662* 
subtype of nAChR relative to its interaction With the MTBZ 
site on VMAT2, as indicated by its ability to inhibit nicotine 
evoked [3H]DA release. Moreover, Compound 15 exhibits 
very good selectivity (>24-fold) for the 0662* subtype of 
nAChR compared to its interaction With either 01462* or 017* 
subtypes of nAChR. Furthermore, Compound 15 Was only 
22-fold more selective as an inhibitor of the 0662* subtypes 
of nAChR compared to its inhibition of SERT function. 
Finally, Compound 15 interacted With SERT 4.3-fold more 
selectively than it interacted With VMAT2. 
The earlier data shoWs that Compound 14 Was 18-fold 
more potent at inhibiting nicotine-evoked [3H]DA and [3 H] 
NE release from rat striatal and hippocampal slices, indi 
cated a higher affinity for the 0662* and 06 64* subtypes of 
nAChRs, compared to Compound 15. On the other hand, 
Compound 15 Was 19-fold more potent inhibiting the func 
tion of SERT than Was Compound 14. Finally, Compound 14 
Was only 4-fold more potent interacting With VMAT2 com 
pared to Compound 15. Thus, alteration of stereochemistry 
at C2 and C6 from cis to trans resulted in a diminished 
af?nity for the 0662* subtypes of nAChR and for VMAT2, 
and enhanced the affinity for SERT, Whereas there Was no 
change in affinity for either 01462* or 017* subtypes of 
nAChR. Therefore, cis-analogs have higher af?nity for 
VMAT2 and 0662* subtype of nAChRs.studies. 
The 2,6-disubstituted piperidino and 2,6-disubstituted 
piperaZino analogs of the present invention exhibit selectiv 
ity for either neuronal nicotinic acetylcholine receptors 
TABLE 4 
Inhibition of 
Nicotine- Inhibition of Inhibition of 
[3H]Nicotine [3H]MLA Evoked 86Rb’“ Nicotine- Nicotine- Inhibition of [3H]5-HT 
(K1) (K1) (1050) Over?oWb (1050) Over?oWb (1050) binding (1050) (1050) 
Compound (1452* (17* (1452* (1652* (1354* VMAT2 SERT 
14 11 11M >100 11M >10 M 0.03 11M 0.021 1.29 11M 23.2 M 
15 13 11M >100 11M ND 0.54 11M ND 5.15 11M 1.19 M 
aInhibition ofl 11M S(—)-nicotine 
bInhibition of 10 11M S(—)-nicotine 
The tWo 2,6-disubstituted piperidino analogs in Table 4 
have the chemical structure of Formula II, and Were assayed 
for interaction With 0462*, 017*, 0662* and 0664* subtypes 
of nAChRs, interaction With VMAT2 located on vesicle 
membranes and inhibition of SERT function. It shall be 
noted that the nAChR subtypes for the activities described 
herein have not been elucidated conclusively, and thus, the 
asterisk is an indication of the putative nature of the receptor 
subtype mediating the action. Compound 14 exhibits good 
selectivity (43-fold) for the 0662* subtype of nAChR rela 
tive to its interaction With the MTBZ site on VMAT2, as 
indicated by its ability to inhibit nicotine-evoked [3H]DA 
release. Moreover, Compound 14 exhibits very good selec 
tivity (>370-fold) for the 0662* and 0664* subtypes of 
nAChRs compared to its interaction With either 01462* or 
017* subtypes of nAChR. Furthermore, Compound 14 Was 
770-fold more selective as an inhibitor of the 0662* and 
0664* subtypes of nAChR compared to its inhibition of 
SERT function. Finally, Compound 14 interacted With 
VMAT2 18-fold more potently than With SERT. 
Compound 15 Was also assayed for interaction With 
nAChRs subtypes, interaction With VMAT2 located on 
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and/or the DAT, SERT, NET or VMAT2. The analogs that 
are active toWards the nicotinic receptor generally do not 
interact With the DAT, and those that interact With the DAT 
shoW only modest nicotinic receptor activity. 
The invention Will noW be discussed by certain examples 
that illustrate but do not limit the invention. 
EXAMPLE 1 
Cis-2,6-di-trans-styrylpiperidine 
1.00 g (2.95 mmol) oflobelanidine Was dissolved in 15 ml 
of 85% H3PO4 and alloWed to stir overnight at 60° C. The 
reaction mixture Was taken up in H20 and made basic With 
solid KZCO3 (pH~8). The pH Was adjusted by the addition 
of solid NaOH (pH~10). The aqueous solution Was extracted 
three times With 15 ml of EtOAc. The organic layers Were 
combined and dried over anhydrous MgSO4. The salts Were 
removed via ?ltration and solvent removed by rotary evapo 
ration alfording 0.70 g of crude product. This compound Was 
recrystallized from MeOH affording 0.60 g of pure cis-2,6 
di-trans-styrylpiperidine. Percent yield:78.6% Mp:139 
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1410 C. 1H NMR (300 MHZ, CDCl3) d: 1.40-1.80 (m, 6H), 
2.23 (s, 3H), 2.50-2.64 (t, 2H), 6.04-6.20 (dd, 2H), 6.39-6.50 
(d, 2H) and 7.10-7.38 (m, 10H); 13C NMR (CDCl3) d: 23,75, 
33.56, 42.32, 68.36, 126.26, 127.38, 128.61, 130.52, 133.89 
and 137.13 ppm. 
EXAMPLE 2 
Preparation of cis- and 
trans-2,6-di-trans-styrylpiperidine 
NaBH4 
—> 
ethanol 
CH3 
l/2 H2804 
Lobeline 
OH O OH 
@AWW N """’l)\® + 
CH3 
Lobelanidine 
I 85% H3PO4 
isomers —>
<;>/\\\““vo?lqlll/\® + 
CH3 
Cis-Z,6-di-trans-styrylpiperidine 
CH3 
Trans-2,6-di-trans-stryrylpiperidine 
To a suspension of L-lobeline hemisulfate salt (85%, 10.5 
g) in absolute ethanol (300 mL) Was added NaBH4 (1.5 eq.) 
portionWise at 0° C. The mixture Was stirred at 0° C. for 1 
hour, and then quenched With acetone. The mixture Was 
evaporated under reduced pressure. Water (100 mL) Was 
added to the residue and extracted With chloroform (80 
mL><3). The combined organic extract Was dried (MgSO4), 
?ltered and evaporated to afford lobelanidine as a White solid 
Which Was used directly. An analytical sample Was recrys 
talliZed from acetone/hexane as a needle crystal. Mp 142 
143° C.; 1H NMR (300 MHZ, CDCl3) 6 1.15 (m, 2H), 
1.44-1.82 (m, 6H), 2.04 (ddd, 1:144, 10.2, 8.7 HZ, 2H), 2.35 
(s, 3H), 2.96 (m, 2H), 4.89 (dd, 1:87, 5.1 HZ, 2H), 7.23-7.50 
(m, 10H); 13C NMR (75 MHZ, CDCl3) 6 23.48, 25.20, 
25.96, 41.79, 62.37, 74.30, 125.98, 127.50, 128.55, 144.88 
ppm. 
Crude lobelanidine Was dissolved in 130 mL 85% H3PO4 
and alloWed to stir at 60° C. for 24 hours. The reaction 
mixture Was cooled to room temperature, diluted With 250 
mL Water and made basic With solid NaOH (pH~10). The 
aqueous solution Was extracted With EtOAc (150 mL><3). 
The combined organic extract Was dried (MgSO4), ?ltered 
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and concentrated under reduced pressure. The crude product 
Was recrystalliZed from acetone affording 2.2 g of pure 
cis-2,6-di-trans-styrylpiperidine as a White solid. Mp: 105 
106° C.(HCl salt); 1H NMR (300 MHZ, CDCl3) 6 1.42-1.88 
(m, 6H), 2.25 (s, 3H), 2.63 (m, 2H), 6.21 (dd, 1:159, 9.0, 
2H), 6.51 (d, 1:159, 2H), 7.19-7.41 (m, 10H); 13C NMR (75 
MHZ, CDCl3) 6 24.14, 33.94, 42.61, 68.56, 126.32, 127.46, 
128.69, 130.51, 134.03, 137.17 ppm. The remaining mother 
liquor Was evaporated and the residue Was chromatographed 
(SiO2, EtOAc/hexanes, 1/ 10) to afford cis-2,6-di-trans 
styrylpiperidine 1.4 g and trans-2S, 6S-di-trans-styrylpiperi 
dine 230 mg. Mp: 200-202° C. (HCl salt); 1H NMR (300 
MHZ, CDCl3) 6 1.60-1.75 (m, 4H), 1.82-1.97 (m, 2H), 2.27 
(s, 3H), 3.38 (m, 2H), 6.38 (dd, 1:159, 8.7, 2H), 6.52 (d, 
1:159, 2H), 7.17-7.42 (m, 10H); 13C NMR (75 MHZ, 
CDCl3) 6 19.57, 32.92, 41.96, 62.29, 126.39, 127.50, 
128.69, 130.49, 131.78, 137.20 ppm. 
EXAMPLE 3 
Cis-10R,2S,6R- and Cis-10S,2S,6RiN-methyl-6 
[1 -(2-hydroxy-2-phenyl)-ethyl]-2-trans-styrylpiperi 
dine 
In a 250 ml round bottom ?ask Was added 0.80 g of 
cis-2S,6RiN-methyl-6-phenacyl-2-trans-styrylpiperidine, 
and 50 ml of ethanol. Sodium borohydride Was added until 
all of the starting material Was consumed (determined by 
TLC). The solution Was cooled to 0° C. and acetone Was 
added in small portions to quench the reaction. The solvents 
Were evaporated to dryness and Water Was added precipi 
tating 0.75 g of an off-White crystalline solid (1:1) mixture 
of diastereomers, Which Was puri?ed on silica eluting With 
75:25 (CHCl3/EtOH). The yield of the product (a mixture of 
diastereomers) Was 93.4%. 1H NMR (300 MHZ, CDCl3) 6: 
1.17-2.06 (m, 12H), 2.12 (s, 3H), 2.35 (s, 3H), 2.50-6.20 (m, 
4H), 2.70-3.20 (m, 4H), 4.78-4.80 (dd, 1H), 5.04-5.14 (dd, 
1H), 5.96-6.20 (m, 2H), 6.32-6.42 (dd, 2H) and 7.04-7.34 
(m, 20H); 13C NMR (CDCl3) 6: 23.69, 24.15, 26.74, 29.68, 
33.26, 39.94, 41.10, 41.41, 62.93, 63.00, 65.62, 68.32, 
71.76, 73.90, 125.46, 126.15, 126.19, 126.83, 127.01, 
127.37, 128.16, 128.23, 128.50, 130.58, 132.61, 133.85, 
136.83, 136.95, 145.32 and 145.45 ppm. 
EXAMPLE 4 
Cis-2S, 6RiN-methyl-6- [1 -(2 -hydroxy-2 -phenyl) 
ethyl] -2 -phenylethylpip eridine 
0.50 g (1.55 mmol) of cis-2S,6RiN-methyl-6-phenacyl 
2-trans-styrylpiperidine Was dissolved in 50 ml of ethanol 
and placed into a Parr hydrogenation apparatus With 0.10 g 
of 10% Pd-on-Carbon. After removal of air, hydrogen gas 
Was introduced until a pressure of 40 psig Was reached. The 
reaction Was alloWed to proceed for 48 hours. The Pd 
catalyst Was removed through ?ltration With Celite, and 
ethanol Was removed by rotary evaporation to afford 0.30 g 
of a yelloW oil. The compound Was puri?ed by silica gel 
chromatography eluting With EtOAc to afford 0.25 g of the 
product. The yield Was 50.0%. 1H NMR (300 MHZ, CDCl3) 
6: 0.70-0.90 (m, 6H), 1.18 (s, 3H), 1.40-1.90 (m, 6H), 
2.44-2.56 (m, 2H), 4.56-4.60 (dd, 1H) and 7.04-7.30 (m, 
10H); 13C NMR (CDCl3) 6: 25.77, 29.24, 29.38, 29.42, 
29.46, 29.68, 31.44, 35.93, 39.07, 74.64, 125.50, 125.85, 
127.42, 128.17, 128.35, 128.37, 142.85 and 144.91 ppm. 
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EXAMPLE 5 
Preparation of Compound 2:2S,6R,8S-2-[6-([3-Para 
to luenesul fonyl oxyphenethyl) - 1 -methyl -2 -pip - 
eridyl] -acetophenone 
OH O O 
\\\\\,.- N “0,”, _) 
CH3 
Compound 1 
0 CH3 
/ S 
o/ | 
O O O 
\\\““‘ N '“"1” 
CH3 
Compound 2 
1.00 g (2.58 mmol) of lobeline hemisulfate Was dissolved 
in 25 ml of pyridine and Was added dropWise to a solution 
(cooled to 0° C.) containing 0.60 g (3.14 mmol) of p-tolu 
enesulfonyl chloride dissolved in 15 ml of pyridine. After 
addition, the reaction Was alloWed to stir for 2 hours and then 
poured into 50 ml of ice-cold Water and the mixture Was 
stirred for an additional tWo hours. The aqueous solution 
Was extracted three times With 25 ml of EtOAc. The organic 
layers Were combined and dried over anhydrous Na2SO4. 
The salts Were removed by ?ltration and the solvent Was 
removed by rotary evaporation a?‘ording 450 mg of a 
pink-colored compound. The product Was recrystallized 
from acetone yielding 300 mg of the product. Yield: 21.6%. 
mp:169-171° C.;lH NMR (300 MHZ, CDCl3) 6 1.30-1.98 
(m, 6H), 2.20 (s, 3H), 2.63-2.74 (d, 3H), 2.95-3.20 (m, 2H), 
3.61-3.78 (d, 1H), 3.83-4.12 (m, 2H), 4.50-4.72 (m, 1H), 
4.80-4.90 (d, 1H), 6.90-7.00 (d, 2H), 7.10-7.50 (m, 8H), 
7.50-7.60 (d, 2H), 7.80-7.90 (d, 2H) and 9.85 (s, 1H) ppm; 
13C NMR (75 MHZ, CDCl3) 6 21.16, 22.25, 23.32, 23.55, 
27.35, 38.29, 40.18, 40.07, 60.79, 63.69, 71.05, 125.56, 
125.76, 127.39, 128.28, 128.44, 128.69, 128.77, 133.67, 
133.96, 135.87, 140.03, 141.98, 144.47, 195.21 ppm. 
EXAMPLE 6 
Preparation of Compound 5: 
N-methyl-2R-phenacyl-6S-trans-styrylpiperidine 
N 
CH3 
Compound 1 
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-continued 
null/l 
CH3 
C ornp ound 5 
1.00 g (2.58 mmol) of lobeline hemisulfate Was dissolved 
in 15 ml of 85% H3PO4 and the solution Was alloWed to stir 
for 24 hours at 50° C. Phosphoric acid Was then neutraliZed 
With K2CO3, and a little ice cold H2O Was added to dissolve 
the salts. The aqueous solution Was extracted With ethyl 
acetate (20 mL><3). The organic layers Were combined and 
dried With anhydrous MgSO4. The salts Were removed by 
?ltration and the solvent Was removed via rotary evapora 
tion, a?‘ording 0.80 g of a gummy solid. Yield: 84.6%. 1H 
NMR (300 MHZ, CDCl3) 6 1.15-1.60 (m, 6H), 2.02 (s, 3H), 
2.47-2.71 (m, 3H), 3.16-3.34 (dd, 1H), 5.80-6.00 (dd, 1H), 
6.18-6.28 (d, 1H), and 6.90-7.38 (m, 8H) and 7.64-7.80 (d, 
2H) ppm; 13 C NMR (CDCl3) 6 23.52, 32.56, 33.17, 40.52, 
44.02, 59.62, 68.08, 126.00, 127.15,127.92,128.36, 128.44, 
130.29, 132.91, 133.91, 136.95, 136.99, 198.83 ppm. 
EXAMPLE 7 
Preparation of Compound 6 and 7: N-Methyl-2R 
(2R-hydroxy-2-phenethyl)-6S-trans-styrylpiperidine 
and N-Methyl-2R-(2S-hydroxy-2-phenethyl)-6S 
trans-styrylpiperidine 
Compound 5 
O OH 
\ \\\\“‘_ N ""01, 
I + 
CH3 
Compound 6 
0 9H 
\ \\\\““ N ""1", 
CH3 
C ornp ound 7 
To a solution of compound 5 (1.25 g, 3.91 mmol) in 
absolute ethanol (40 mL) Was added NaBH4 (296 mg, 7.82 
mmol) at 0° C. The mixture Was stirred for 2 h at 0° C., and 
then quenched With acetone. The solvents Were evaporated 
under reduced pressure, and the residue Was suspended in 
Water (80 mL) and extracted With CHCl3 (3x50 mL). The 
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combined organic extract Was dried (Na2SO4), ?ltered and 
concentrated. Flash chromatography (CHCl3/CH3OH/ 
NH4OH 20:1:0.2) gave a 9:20 mixture of compound 6 and 
7 as a White solid. Recrystallization from hexanes a?‘orded 
6 (308 mg, 24%) as a White solid. The remained mixture Was 
puri?ed by column chromatography (CHCl3/CH3OH/ 
NH4OH 50:l:0.2) to give 7 (511 mg, 41%) as a White solid. 
Compound 6: [0t]D25 41.5 (c 1.0, CHCl3); mp 104-1050 C.; 
1H NMR (300 MHZ, CDCl3) 6: 1.42-1.72 (m, 6H), 1.87 (m, 
1H), 2.04 (m, 1H), 2.32 (s, 3H), 2.93 (m, 1H), 3.28 (m, 1H), 
4.98 (dd, 1:105, 3.3 HZ, 1H), 6.23 (dd, 1:162, 6.3 HZ, 1H), 
6.45 (d, 1:162 HZ, 1H), 7.20-7.42 (m, 10H) ppm; 13C NMR 
(75 MHZ, CDCl3) 6 24.6, 26.7, 33.0, 41.5, 63.4, 65.5, 74.6, 
125.6, 126.3, 127.2, 127.5, 128.4, 128.7, 130.4, 133.1, 
137.2, 145.4 ppm; MS m/Z 321 (M+); Compound 7: mp 
117-1180 C.; [0t]D25-131.0 (c 1.0, CHC3); 1H NMR (300 
MHZ, CDCl3) 6 1.35-1.64 (m, 3H), 1.66-1.80 (m, 2H), 1.87 
(m, 1H), 2.02 (m, 1H), 2.45 (m, 1H), 2.47 (s, 3H), 2.65 (m, 
1H), 5.20 (dd, J:11.1, 3.3 HZ, 1H), 6.13 (dd, 1:162, 8.4 HZ, 
1H), 6.47 (d, 1:162 HZ, 1H), 7.20-7.42 (m, 10H); 13C 
NMR (75 MHZ, CDCl3) 6 24.0, 30.0, 33.7, 40.2, 41.6, 63.3, 
68.6, 72.1, 125.6, 126.3, 127.0, 127.5, 128.3, 128.7, 130.7, 
134.1, 137.0, 145.4 ppm; MS m/Z 321 (M+). 
EXAMPLE 8 
Preparation of Compound 10: N-Methyl-2R-(2R 
hydroxy-2-phenethyl)-6S-(2-phenethyl) piperidine 
Compound 6 
C omp ound l 0 
Compound 6 (230 mg, 0.72 mmol) Was suspended in 
absolute methanol (30 mL) and 10% Pd/C (30 mg) Was 
added. The mixture Was hydrogenated on a Parr hydroge 
nation apparatus (45 psi) for 36 hours. The catalyst Was 
removed by ?ltration through Celite. The ?lter cake Was 
rinsed With methanol, and the combined organic portions 
Were concentrated under reduced pressure. The resulting 
residue Was puri?ed by column chromatography (CHCl3/ 
CH3OH/NH4OH 40:1:0.2) to a?cord 10 (187 mg, 81%) as 
colorless oil. [0t]D25 65.5 (c 1.0, CHCl3); 1H NMR (300 
MHZ, CDCl3) 6 1.14 (m, 1H), 1.25 (m, 1H), 1.45-1.70 (m, 
5H), 1.76-2.04 (m, 3H), 2.30 (s, 3H), 2.57-2.79 (m, 2H), 
2.87 (m, 1H), 3.20 (m, 1H), 5.01 (dd, 1:108, 3.0 HZ, 1H), 
7.15-7.43 (m, 10H) ppm; 13C NMR (75 MHZ, CDCl3) 6 
23.7, 23.9, 25.4, 25.7, 32.6, 36.0, 40.2, 62.0, 65.0, 76.4, 
125.6, 125.9, 127.1, 128.4,128.5,128.6, 142.3, 145.2 ppm; 
MS m/Z 323 (M’'); 
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EXAMPLE 9 
Preparation of Compound 11: N-Methyl-2R-(2S 
hydroxy-2-phenethyl)-6S-(2-phenethyl) piperidine 
CH3 
C omp ound 7 
Compound 1 l 
Compound 11 Was prepared as described above for 10 
from 7 (122 mg, 0.38 mmol) to give 92 mg (75%) ofproduct 
as colorless oil. [0t]D25-75.4 (c 1.0, CHCl3); 1H NMR (300 
MHZ, CDCl3) 6 1.26-1.44 (m, 2H), 1.44-1.57 (m, 2H), 
1.67-2.00 (m, 6H), 2.36 (m, 1H), 2.39 (s, 3H), 2.60-2.72 (m, 
3H), 5.14 (t, 1:60 HZ, 1H), 7.15-7.40 (m, 10H) ppm; 13C 
NMR (75 MHZ, CDCl3) 6 24.7, 26.7, 31.5, 33.7, 36.1, 39.1, 
61.8, 62.8, 72.5, 125.7, 125.9, 126.8, 128.3, 128.5, 142.4, 
145.7 ppm; MS m/Z 323 (M+); 
EXAMPLE 10 
Preparation of Compound 14 and 15: N-methyl-2, 
6-cis-di-trans-styrylpiperidine and N-methyl-2S,6S 
trans-di-trans-styrylpiperidine 
C omp ound l 
Compound 14 
C omp ound l 5 
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(—)-Lobeline semisulfate salt (1.85 g) Was dissolved in 
saturated aqueous K2CO3 (60 mL) and extracted With CHCl3 
(3x30 mL). The combined organic phase Was dried over 
anhydrous K2CO3 for 48 hours, ?ltered and concentrated to 
a?cord a mixture of 2R, 6S- and 2S, 6 S-lobeline free base in 
nearly equal ratio (determined by NMR) as a White solid 
(1.35 g, 4.00 mmol), Which Was suspended in absolute 
ethanol (40 mL) and NaBH4 (300 mg, 8.00 mmol) Was 
added at room temperature. The mixture Was stirred for 1 
hour, and then quenched With acetone. The solvents Were 
evaporated under reduced pressure, and the residue Was 
suspended in Water (60 mL) and extracted With CHCl3 (3x50 
mL). The combined organic extract Was dried (Na2SO4), 
?ltered and concentrated to give a mixture of lobelanidine 
and its isomers as a White solid Which Was used directly. The 
crude product Was dissolved in 85% H3PO4 (40 mL) and 
alloWed to stir at 600 C. for 24 hours. The reaction mixture 
Was cooled to room temperature, diluted With Water (150 
mL) and made basic With solid K2CO3 and then NaOH 
(pH~10). The aqueous solution Was extracted With EtOAc 
(3x80 mL). The combined organic extract Was dried 
(Na2SO4), ?ltered and concentrated. The crude product Was 
puri?ed by column chromatography (10:1 to 1:1 hexanes: 
ethylacetate gradient) to give title Compound 14 (390 mg, 
32%) and 15 (341 mg, 28%) as White solids. Compound 14: 
mp 149-1500 C.; 1H NMR (300 MHZ, CDCl3) 6 1.42-1.88 
(m, 6H), 2.25 (s, 3H), 2.63 (m, 2H), 6.21 (dd, 1:159, 9.0 HZ, 
2H), 6.51 (d, 1:159 HZ, 2H), 7.19-7.41 (m, 10H) ppm; 13C 
NMR (75 MHZ, CDCl3) 6 24.1, 33.9, 42.6, 68.6, 126.3, 
127.5, 128.7, 130.5, 134.0, 137.2 ppm; MS m/Z 303 (M+). 
Compound 6b: [0t]D25-180.2 (c 1.0, CHCl3) mp 93-940 C.; 
1H NMR (300 MHZ, CDCl3) 6 1.60-1.75 (m, 4H), 1.82-1.97 
(m, 2H), 2.27 (s, 3H), 3.38 (m, 2H), 6.38 (dd, 1:159, 8.7 HZ, 
2H), 6.52 (d, 1:159 HZ, 2H), 7.17-7.42 (m, 10H) ppm; 13C 
NMR (75 MHZ, CDCl3) 6 19.6, 32.9, 42.0, 62.3, 126.4, 
127.5, 128.7, 130.5, 131.8, 137.2 ppm; MS m/Z 303. 
EXAMPLE 11 
Preparation of Compound 16: 
N-methyl-2R,6R-trans-di-trans-styryl piperidine 
Compound 14 
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CH3 
C omp ound l 6 
To a solution of Compound 8 (680 mg, 2.16 mmol) in 
CHZCl2 (35 ml) Was added celite (1 g) and PCC (912 mg, 
4.23 mmol) at room temperature. The mixture Was stirred for 
6 h at rt, and then ?ltered through silica gel column, Washed 
With 10% MeOH in CHCl3. The product Was kept at room 
temperature for 48 hours before removed the solvents, and 
then folloWing the similar procedure for Compounds 14 and 
15, Compound 16 Was prepared to give 115 mg (18%) as a 
White solid along With Compound 14. Yield: 112 mg (17%). 
[0t]D25 182.8 (c 1.0, CHCl3); mp 92-930 C.; 1H NMR (300 
MHZ, CDCl3) 6 1.62-1.75 (m, 4H), 1.80-1.96 (m, 2H), 2.28 
(s, 3H), 3.38 (m, 2H), 6.38 (dd, 1:159, 8.7 HZ, 2H), 6.52 (d, 
1:159 HZ, 2H), 7.20-7.42 (m, 10H) ppm; 13C NMR (75 
MHZ, CDCl3) 6 19.6, 32.9, 41.9, 62.3, 126.4, 127.5, 128.7, 
130.5, 131.7, 137.2 ppm; MS m/Z 303. 
EXAMPLE 12 
Preparation of Compound 17: N-methyl-2,6-cis-di-(2 
phenethyl)piperidine 
l 
CH3 
C omp ound l 4 
C omp ound l 7 
Compound 14 (420 mg, 1.38 mmol) Was dissolved in 
methanol (50 mL) and 10% Pd/C (40 mg) Was added. The 
mixture Was hydrogenated on a Parr hydrogenation appara 
tus (45 psi) for 18 hours. The catalyst Was removed by 
?ltration through Celite. The ?lter cake Was rinsed With 
methanol, and the combined organic portions Were concen 
trated under reduced pressure. The resulting residue Was 
puri?ed by column chromatography to a?cord Compound 17. 
Yield: 223 mg (53%) as a White solid. mp 171-1720 C.; 1H 
NMR (300 MHZ, CDCl3) 6 1.30-1.42 (m, 4H), 1.60-1.85 (m, 
6H), 2.19 (s, 3H), 2.32-2.44 (m, 2H), 2.60-2.77 (m, 4H), 
7.12-7.35 (m, 10H) ppm; 13C NMR (75 MHZ, CDCl3) 6 
25.4, 27.1, 31.0, 32.5, 36.6, 62.7, 125.7, 128.4, 128.5, 143.0 
ppm; MS m/Z 307 (M+). 
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EXAMPLE 13 
Preparation of Compound 18: 
N-methyl-2S,6S-trans-di-(2-phenethyl)piperidine 
Compound 15 
N 
CH3 
C omp ound l 8 
Compound 18 Was prepared as described above for Com 
pound 17 from Compound 15 (100 mg, 0.33 mmol) to give 
52 mg (51%) of product as a colorless oil. [0t]D25—35.4 (c 
0.5, CHCl3); 1H NMR (300 MHZ, CDCl3) 6 1.37-1.52 (m, 
2H), 1.55-1.75 (m, 6H), 1.81-1.95 (m, 2H) 2.36 (s, 3H), 
2.55-2.67 (m, 4H), 2.67-2.78 (m, 2H), 7.14-7.35 (m, 10H) 
ppm; 13C NMR (75 MHZ, CDCl3) 6 20.1, 26.6, 32.4, 33.1, 
37.9, 57.6, 125.8, 128.4, 128.5, 142.9 ppm; MS m/Z 307 
(M+). 
EXAMPLE 14 
Preparation of Compound 19: 
N-methyl-2R,6R-trans-di-(2-phenethyl)piperidine 
\ N “000/ | ’ 
CH3 
Compound 16 
N “.0”, 
CH3 
Compound 19 
Compound 19 Was prepared as described above for Com 
pound 17 from Compound 16 (108 mg, 0.36 mmol) to give 
53 mg (48%) ofproduct as a colorless oil. [611,25 36.0 (c 1.0, 
CHCl3); 1H NMR (300 MHZ, CDCl3) 6 1.37-1.52 (m, 2H), 
1.55-1.75 (m, 6H), 1.81-1.95 (m, 2H) 2.36 (s, 3H), 2.55-2.67 
(m, 4H), 2.67-2.78 (m, 2H), 7.14-7.35 (m, 10H); 13C NMR 
(75 MHZ, CDCl3) 6 20.1, 26.6, 32.4, 33.1, 37.9, 57.6, 125.8, 
128.4, 128.5, 142.9 ppm; MS m/Z 307 (M’'). 
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EXAMPLE 15 
Preparation of Compound 20: N-methyl-2R-(2 
phenethyl)-6S-trans-styrylpiperidine 
C omp ound l 2 
Compound 20 
Compound 20 Was prepared by dehydration method as 
described above for compound 14 and 15 from compound 
12 (419 mg 1.30 mmol) to give 215 mg (54%) ofproduct as 
White solid. [0t]D25—51.5 (c 1.0, CHCl3); mp 72-730 C.; 1H 
NMR (300 MHZ, CDCl3) 6 1.30-1.84 (m, 7H), 1.92-2.09 (m, 
2H), 2.27 (s, 3H), 2.51-2.69 (m, 2H), 2.70-2.83 (m, 1H), 
6.21 (dd, 1:159, 8.4 HZ, 1H), 6.47 (d, 1:159 HZ, 1H), 
7.15-7.40 (m, 10H) ppm; 13C NMR (75 MHZ, CDC13) 6 
24.5, 31.2, 31.9, 33.7, 36.2, 40.2, 63.9, 68.9, 125.8, 126.3, 
127.4, 128.4, 128.5, 128.7, 130.2, 134.8, 137.3, 142.9 ppm; 
MS m/Z 305 (M+). 
EXAMPLE 16 
Preparation of compounds 21 and 22: N-methyl 
2R-trans-styryl-6S-(2-phenethyl)piperidine and 
N-methyl-2S-trans-styryl-6S-(2-phenethyl)piperidine 
C omp ound 5 
T + 
CH3 
Compound 21 
US 
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cH3 
Compound 22 
Compound 5 (1.20 g, 3.76 mmol) Was dissolved in CHCl3 
(100 mL) and kept at room temperature for 48 hours. The 
solvent Was removed under reduced pressure and the residue 
Was dissolved in 10% HOAc/CH3OH (100 mL) and 10% 
Pd/C (120 mg) Was added. The mixture Was hydrogenated 
on a Parr hydrogenation apparatus (45 psi) for 24 hours. The 
catalyst Was removed by ?ltration through Celite. The ?lter 
cake Was rinsed With methanol, and the combined organic 
portions Were concentrated under reduced pressure. The 
crude product Was dissolved in 85% H3PO4 (30 mL) and 
alloWed to stir at 60° C. for 24 hours. The reaction mixture 
Was cooled to room temperature, diluted With Water (100 
mL) and made basic With solid K2CO3 and then NaOH 
(pH~10). The aqueous solution Was extracted With EtOAc 
(3><80 mL). The combined organic extract Was dried 
(MgSO4), ?ltered and concentrated. The crude product Was 
puri?ed by column chromatography (4:1 to 1:1 hexanes: 
ethylacetate gradient) to give Compound 21 (188 mg, 16%) 
as a White solid and Compound 22 (167 mg, 15%) as a 
colorless oil. Compound 21: [0t]D25 53.8 (c 1.0, CHCl3); mp 
75-760 C.;1H NMR (300 MHZ, CDCl3) 6 1.30-1.89 (m, 7H), 
1.92-2.09 (m, 2H), 2.27 (s, 3H), 2.51-2.69 (m, 2H), 2.70 
2.83 (m, 1H), 6.21 (dd, 1:159, 8.4 HZ, 1H), 6.47 (d, 1:159 
HZ, 1H), 7.15-7.40 (m, 10H) ppm; 13C NMR (75 MHZ, 
CDCl3) 6 24.5, 31.3, 31.9, 33.7, 36.2, 40.3, 63.9, 68.9, 
125.8, 126.3, 127.4, 128.4, 128.5, 128.7, 130.2, 134.9, 
137.3, 142.9 ppm; MS m/Z 305 (M+). Compound 22: 
[0t]D25—103.6 (c1.0, CHCl3); 1H NMR (300 MHZ, CDCl3) 
6 1.50-1.82 (m, 7H), 1.84-1.98 (m, 1H), 2.32 (s, 3H), 2.51 
(ddd, 1:135, 10.8, 5.7 HZ, 1H), 2.68 (ddd, 1:135, 10.8, 5.4 
HZ, 1H), 2.83 (m, 1H), 3.23 (m, 1H), 6.28 (dd, 1:159, 8.4 
HZ, 1H), 6.47 (d, 1:159 HZ, 1H), 7.13-7.39 (m, 10H) ppm; 
13C NMR (75 MHZ, CDCl3) 6 19.4, 28.9, 29.1, 32.2, 33.2, 
40.7, 58.6, 61.8, 125.9, 126.4, 127.4, 128.4, 128.5, 128.7, 
131.0, 132.0, 137.3, 142.7 ppm; MS m/Z 305 (M+). 
EXAMPLE 17 
Preparation of Compounds 23 and 24: 2,6-cis-di 
trans-styrylpiperidine and (:)-2,6-trans-di-trans 
styrylpiperidine 
\\\\\OIIIII \\\ N 1,, —> 
H —> 
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H + 
Compound 23 
\\ \\ \\ \\ 
m2 
C omp ound 24 
Cis-nor-lobelanine Was prepared according to reported 
method (Ebnother, 1958). With the similar procedure as 
Compounds 14 and 15 from (—)-lobeline 1, Compounds 23 
and 24 Were obtained in pure form. Compound 23: 1H NMR 
(300 MHZ, CDCl3) 6 0.78 (t, 1:75 HZ, 3H), 1.28-1.60 (m, 
3H), 1.68-1.84 (m, 2H), 1.91 (m, 1H), 3.37 (m, 2H), 6.26 
(dd, 1:159, 7.2 HZ, 2H), 6.54 (d, 1:159 HZ, 2H), 7.17-7.40 
(m, 10H) ppm; 13C NMR (75 MHZ, CDCl3) 6 24.7, 32.4, 
59.7, 126.4, 127.4, 128.6, 129.6, 133.4, 137.2 ppm; MS m/Z 
289 (M’'), 198 (100), 156, 129,115,91.lHNMR(300 MHZ, 
CDCl3) 6 0.78 (t, 1:75 HZ, 3H), 1.53-1.90 (m, 6H), 3.78 (m, 
2H), 6.41 (dd, 1:159, 6.3 HZ, 2H), 6.52 (d, 1:159 HZ, 2H), 
7.19-7.43 (m, 10H) ppm; 13C NMR (75 MHZ, CDCl3) 6 
20.3, 31.5, 53.8, 126.4, 127.5, 128.7, 129.9, 132.8, 137.3 
ppm; MS m/Z 289 (M’'), 198 (100), 156, 129, 115,91. 
EXAMPLE 18 
Preparation of Compounds 25-55 
Compounds 25-55 Were prepared as illustrated in the 
Scheme 1 beloW: 
Schemel 
\ 
IN/ — 
\ 
Reagents and conditions: (a) ArCHO, AcZO, re?ux; (b) 
Pt2O/H2, HOAc; (c) R=CH3, (CH2O)n, NaCNBH3, MeOH; 
R=CH2CH3, Etl, K2CO3, THF, re?ux, 72 h; 
R=CH2CH2CH3, 1-Prl, K2CO3, THF, re?ux, 72 h. The 
general procedure for preparing 2,6-di-arylenethenylpyri 
dine, 2,6-cis-diarylethylpiperidine, N-methyl-2,6-cis-diaryl 
ethylpiperidine compounds is set forth beloW. 
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2,6-Di-arylenethenylpyridines: The mixture of 2,6-luti 
dine (5.32 g, 50 mmol), aryl aldehyde (105 mmol) and acetic 
anhydride (10 mL) Was re?uxed for 48-72 h and then cooled 
to room temperature. The solidi?ed mixture Was transferred 
to a suction ?lter and the ?lter cake Was Washed With 95% 
ethanol. If the reaction mixture could not be solidi?ed, 95% 
ethanol Was added and stirred until the product Was precipi 
tated. The crude product Was recrystallized from benzene or 
ethanol to a?‘ord title compound as a White crystal. Yield: 
20-93%. 
2,6-Cis-Diarylethylpiperidines: The above 2,6-di-aryle 
nethenylpyridine (10 mmol) Was dissolved in glacial acetic 
acid (30 mL) and PtO2 (1-2% W/W) Was added. The mixture 
Was hydrogenated on a Parr hydrogenation apparatus (45 
psi) for 12-48 hours. The catalyst Was removed by ?ltration 
through Celite. The ?lter cake Was rinsed With methanol, and 
the combined organic portions Were concentrated under 
reduced pressure. The resulting residue Was basi?ed With 
saturated aqueous K2CO3 and the aqueous solution Was 
extracted With CHCl3 (3x50 mL). The combined organic 
extract Was dried (Na2SO4), ?ltered and concentrated. The 
crude product Was puri?ed by column chromatography (30:1 
CHCl3:MeOH) to give title compound. Yield: 53-90%. 
N-methyl-2,6-cis-diarylethylpiperidines: NaCNBH3 (188 
mg, 3 mmol) Was added to the mixture of nor-lobelane (1.00 
mmol), paraformaldehyde (150 mg, 5.00 mmol) and metha 
nol (10 mL). The mixture Was stirred at room temperature 
for 2 hours. The solvent Was then evaporated under reduced 
pressure. The residue Was dissolved Water (30 mL) and the 
aqueous solution Was extracted With CHCl3 (3x20 mL). The 
combined organic extract Was dried (Na2SO4), ?ltered and 
concentrated. The crude product Was puri?ed by column 
chromatography (30:1 CHCl3:MeOH) to give title com 
pound. Yield: >95%. 
Compound 25: 2,6-cis-diphenethylpiperidine 
1H NMR (300 MHZ, CDC13) 6 1.07 (ddd, 1:240, 13.2, 
3.9 HZ, 2H), 1.32 (ddt, 1:264, 12.9, 3.9 HZ), 1.62-1.74 (m, 
6H), 1.78 (dq, 1:132, 3.0 HZ, 1H), 2.50 (m, 2H), 2.63 (1, 
1:81 HZ, 4H), 7.12-7.33 (m, 10H) ppm; 13C NMR (75 
MHZ, CDC13) 6 25.0, 32.7, 32.9, 39.2, 56.9, 125.9, 128.4, 
128.5, 142.3 ppm; Ms m/Z 293 (M+). 
Compound 26: 
N-ethyl-2,6-cis-diphenethylpiperidine 
1H NMR (300 MHZ, CDC13) 6 0.94 (1, 1:72 HZ, 3H), 
1.28-1.48 (m, 3H), 1.56-1.82 (m, 5H), 1.86-2.02 (m, 2H), 
2.46-2.80 (m, 8H), 7.13-7.31 (m, 10H) ppm; 13C NMR (75 
MHZ, CDC13) 6 12.6, 24.5, 28.8, 32.7, 36.0, 39.6, 60.7, 
125.8,128.4,142.7 ppm; Ms m/Z 321 (M*), 281, 216 (100), 
188, 91. 
Compound 27: 
N-(n-propyl)-2,6-cis-diphenethylpiperidine 
1H NMR (300 MHZ, CDC13) 6 0.78 (1, 1:75 HZ, 3H), 
1.28-1.47 (m, 5H), 1.52-1.89 (m, 7H), 2.41-2.78 (m, 8H), 
7.14-7.33 (m, 10H) ppm; 13C NMR (75 MHZ, CDC13) 6 
12.1, 22.3, 24.6, 28.1, 33.1, 36.5, 48.3, 61.6, 125.8, 128.46, 
128.51, 142.8 ppm; Ms m/Z 335 (M), 306, 230 (100), 202, 
91. 
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Compound 28: 
2,6-cis-di-(3,4-methylenedioxyphenethylpiperidine 
1H NMR (300 MHZ, CDC13) 6 1.06 (ddd, 1:240, 12.9, 
3.6 HZ, 2H), 1.31 (ddt, 1:258, 12.9, 3.6 HZ, 1H), 1.52-1.73 
(m, 6H), 1.78 (ddd, 1:132, 6.3, 3.0 HZ, 1H), 2.47 (m, 2H), 
2.55 (1, 1:81 HZ, 4H), 5.90 (s, 4H), 6.62 (dd, 1:78, 1.8 HZ, 
2H), 6.67 (d, 1:18 HZ, 2H), 6.72 (d, 1:78 HZ, 2H) ppm; 13C 
NMR (75 MHZ, CDC13) 6 25.0, 32.4, 32.9, 39.4, 56.7, 100.9, 
108.3, 108.9, 121.1, 136.1, 145.6, 147.6 ppm; Ms m/Z 381 
(1W) 
Compound 29: N-methyl-2,6-cis-di-(3,4-methylene 
dioxyphenethylpiperidine 
1H NMR (300 MHZ, CDC13) 6 1.25-1.49 (m, 4H), 1.60 
1.89 (m, 6H), 2.21 (s, 3H), 2.34 (m, 2H), 2.56 (1, 1:81 HZ, 
4H), 5.94 (s, 4H), 6.64 (dd, 1:78, 1.8 HZ,2H), 6.70 (d, 1:18 
HZ, 2H), 6.75 (d, 1:78 HZ, 2H) ppm; 13C NMR (75 MHZ, 
CDC13) 6 25.4, 29.1, 32.2, 32.7, 37.3, 62.9, 101.8, 108.5, 
109.4, 121.6, 136.8, 144.9, 148.5 ppm; 
Compound 30: 
2,6-cis-di-(o-?uorophenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.08 (ddd, 1:240, 12.9, 
3.9 HZ, 2H), 1.33 (ddt, 1:258, 12.9, 3.9 HZ, 1H), 1.59-1.75 
(m, 6H), 1.79 (ddd, 1:129, 6.0, 3.0 HZ, 1H), 2.50 (m, 1H), 
2.69 (1, 1:78 HZ, 4H), 6.96-7.09 (m, 4H), 7.12-7.22 (m, 4H) 
ppm; 13C NMR (75 MHZ, CDC13) 6 25.0, 25.7, 32.8, 37.9, 
56.8, d(115.150, 115.454), d(124.050, 125.095), d(127.497, 
127.603), d(129.031, 129.243), d(130.534, 130.595), 
d(159.525, 162.760) ppm; M8 329, 206, 109, 
Compound 31: 
N-methyl-2,6-cis-di-(o-?uorophenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.32-1.52 (m, 5H), 1.68 
(m, 2H), 1.74-1.87 (m, 3H), 2.18 (s, 3H), 2.37 (m, 2H), 2.70 
(m, 4H), 6.96-7.06 (m, 4H), 7.12-7.24 (m, 4H) ppm; 13C 
NMR (75 MHZ, CDC13) 6 25.2, 25.7, 27.0, 30.9, 35.0, 62.7, 
d(115.214, 115.435), d(124.035, 124.073), d(127.443, 
127.527), d(129.849, 130.009), d(130.889, 130.943), 
d(160.167, 162.604) ppm; M8 343, 220, 109. 
Compound 32: 
2,6-cis-di-(m-?uorophenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.07 (ddd, 1:240, 13.2, 
3.6 HZ, 2H), 1.33 (ddt, 1:258, 12.9, 3.6 HZ, 1H), 1.58-1.75 
(m, 6H), 1.80 (ddd, 1:129, 6.3, 3.3 HZ, 1H), 2.50 (m, 2H), 
2.64 (1, 1:78 HZ, 4H), 6.83-7.00 (m, 6H), 7.23 (m, 2H) ppm; 
13C NMR (75 MHZ, CDC13) 6 24.9, 32.4, 32.8, 38.9, 56.7, 
d(112.645, 112.918), d(115.135, 115.409), d(124.065, 
124.095), d(129.805, 129.912), d(144.855, 144.961), 
d(164.317, 164.567) ppm; M8 329, 206, 109. 
Compound 33: 
N-methyl-2,6-cis-di-(m-?uorophenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.33-1.50 (m, 5H), 1.65 
(m, 2H), 1.78 (m, 1H) 1.84 (m, 2H), 2.15 (s, 3H), 2.37 (m, 
2H), 2.67 (m, 4H), 6.84-6.94 (m, 4H), 6.97 (d, 1:57 HZ, 
2H), 7.22 (dt, 1:45, 5.7 HZ, 2H) ppm; 13C NMR (75 MHZ, 
CDC13) 6 25.2, 26.7, 30.3, 32.1, 36.1, 62.3, d(112.558, 
112.770), d(115.351, 115.556), d(124.270, 124.293), 
d(129.781, 129.865), d(145.707, 145.775), d(161.883, 
164.319) ppm; Ms m/Z 343, 220, 109 (M+). 
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Compound 34: 
2,6-cis-di-(p-?uorophenethyDpiperidine 
1H NMR (300 MHZ, CDC13) 6 1.08 (ddd, 1:240, 12.9, 
3.6 HZ, 2H), 1.33 (ddt, 1:264, 12.9, 3.6 HZ, 1H), 1.58-1.74 
(m, 6H), 1.80 (ddd, 1:132, 5.7, 3.6 HZ, 1H), 2.49 (m, 2H), 
2.61 (1, 1:78 HZ, 4H), 6.96 (It, 1:90, 2.4 HZ, 4H), 7.12 (dd, 
1:90, 5.4 HZ, 4H) ppm; 13C NMR (75 MHZ, CDC13) 6 25.0, 
31.9, 32.9, 39.4, 56.8, 115.1, 115.4, 129.7, 129.8, 137.8, 
137.9, 159.6, 162.9 ppm; MS m/Z 329 (M+). 
Compound 35: 
N-methy1-2,6-cis-di-(p-?uorophenethy1)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.30-1.51 (m, 5H), 1.63 
(m, 2H), 1.72-1.91 (m, 3H), 2.15 (s, 3H), 2.37 (m, 2H), 2.64 
(m, 4H), 6.95 (11, 1:90, 2.4 HZ, 4H), 7.15 (dt, 1:30, 9.0 HZ, 
4H); 13C NMR (75 MHZ, CDC13) 6 25.3, 26.8, 30.5, 31.7, 
36.7, 62.4, d(114.9, 115.2), d(129.8, 129.9), 138.5, d(159.6, 
162.8) ppm; MS m/Z 343 (M+). 
Compound 36: 
2,6-cis-di-(o -methoxyphenethy1)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.09 (ddd, 1:240, 12.6, 
3.6 HZ, 2H), 1.29 (ddt, 1:255, 12.6, 3.6 HZ, 1H), 1.58-1.76 
(m, 6H), 1.76 (ddd, 1:126, 6.3, 3.0 HZ, 1H), 2.45 (m, 2H), 
2.65 (m, 4H), 3.79 (s, 6H), 6.82 (d, 1:81 HZ, 2H), 6.87 (dt, 
1:75, 1.2 HZ, 2H), 7.10-7.20 (m, 4H) ppm; 13C NMR (75 
MHZ, CDC13) 6 25.0, 26.6, 32.8, 37.8, 55.3, 56.8, 110.2, 
120.5, 127.0, 129.8, 130.7, 157.3 ppm; 
Compound 37: 
N-methy1-2,6-cis-di-(o -methoxyphenethy1)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.36-1.56 (m, 5H), 1.64 
(m, 2H), 1.74-1.90 (m, 3H), 2.21 (s, 3H), 2.35 (brs, 2H), 2.66 
(1, 1:84 HZ, 4H), 3.81 (s, 6H), 6.80-6.92 (m, 4H), 7.10-7.20 
(m, 4H) ppm; 13C NMR (75 MHZ, CDC13) 6 25.4, 27.2, 
27.7, 31.8 34.9, 55.5, 63.4, 110.3, 120.5, 126.9, 129.9, 
131.5, 157.5 ppm. 
Compound 38: 
2,6-cis-di-(m-methoxyphenethy1)piperidine. 
1H NMR (300 MHZ, CDC13) 6 1.08 (ddd, 1:240, 12.9, 
3.6 HZ, 2H), 1.32 (ddt, 1:258, 12.9, 3.6 HZ, 1H), 1.62-1.75 
(m, 6H), 1.79 (ddd, 1:132, 6.3, 3.0 HZ, 1H), 2.50 (m, 2H), 
2.61 (1, 1:81 HZ, 4H), 3.78 (s, 6H), 6.70-6.80 (m, 6H), 
7.16-7.26 (m, 4H) ppm; 13C NMR (75 MHZ, CDC13) 6 25.0, 
32.8, 32.9, 39.1, 55.3, 56.9, 111.2, 114.2, 120.9, 129.4, 
144.0, 159.7 ppm; MS m/Z 353 (M+). 
Compound 39: 
N-methy1-2,6-cis-di-(m-methoxyphenethyDpiperidine 
13H NMR (300 MHZ, CDC13) 6 1.40-1.62 (m, 3H), 1.73 
(m, 2H), 1.82-1.95 (m, 3H), 2.17 (m, 2H), 2.50 (3, 3H), 2.67 
(m, 4H), 3.81 (s, 6H), 6.73-6.82 (m, 6H), 7.21 (dd, 1:90, 7.5 
HZ, 2H) ppm; 13C NMR (75 MHZ, CDC13) 6 22.8, 24.1, 
32.4, 33.6, 55.6, 64.7, 112.4, 113.8, 120.7, 129.8, 141.2, 
159.9 ppm; MS m/Z 367 (M’'). 
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Compound 40: 
2,6-cis-di-(p-methoxyphenethy1)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.08 (ddd, 1:237, 13.2, 
3.3 HZ, 2H), 1.31 (ddt, 1:258, 13.2, 3.3 HZ, 1H), 1.41 (brs, 
1H), 1.58-1.73 (m, 6H), 1.78 (ddd, 1:129, 6.3, 3.3 HZ, 1H), 
2.48 (m, 2H), 2.57 (1, 1:81 HZ, 4H), 3.77 (s, 6H), 6.82 (dd, 
1:87, 3.0 HZ, 4H), 7.09 (dd, 1:87, 3.3 HZ, 4H) ppm; 13C 
NMR (75 MHZ, CDC13) 6 25.0, 31.8, 32.9, 32.9, 39.4, 55.4, 
56.8, 113.9, 129.3, 134.4, 157.8 ppm; MS m/Z 353 (M+). 
Compound 41: 
N-methy1-2,6-cis-di-(p-methoxyphenethy1)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.40 (m, 4H), 1.55-1.70 
(m, 3H), 1.70-1.90 (m, 3H), 2.16 (s, 3H), 2.37 (m, 2H), 2.60 
(m, 4H), 3.78 (s, 6H), 6.82 (d, 1:84 HZ, 4H), 7.12 (d, 1:84 
HZ, 4H) ppm; 13C NMR (75 MHZ, CDC13) 6 25.4, 27.0, 
30.9, 31.6, 36.9, 55.5, 62.6, 113.8, 129.4, 135.1, 157.6 ppm. 
Compound 42: 
2,6-cis-di-(p-methy1phenethy1)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.08 (ddd, 1:240, 12.9, 
3.3 HZ, 2H), 1.32 (m, 1H), 1.58-1.73 (m, 6H), 1.78 (m, 1H), 
2.31 (s, 6H), 2.49 (m, 2H), 2.59 (1, 1:81 HZ, 4H), 7.08 (s, 
8H) ppm; 13C NMR (75 MHZ, CDC13) 6 21.3, 25.1, 32.3, 
32.9, 39.3, 56.9, 128.3, 129.2, 135.3, 139.3 ppm; MS m/Z 
321 (M+). 
Compound 43: 
N-methy1-2,6-cis-di-(p-methy1phenethy1)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.26-1.48 (m, 5H), 1.63 
(m, 2H), 1.75-1.92 (m, 3H), 2.16 (s, 3H), 2.31 (s, 6H), 2.36 
(1511, 1:60 HZ, 2H), 2.50-2.71 (m, 4H), 7.09 (s, 8H) ppm; 
13C NMR (75 MHZ, CDC13) 6 21.3, 25.3, 27.1, 31.0, 32.1, 
36.8, 62.7, 128.4, 129.1, 135.1, 139.9 ppm; MS m/Z 335 
(1W) 
Compound 44: 
2,6-cis-di-(m-tri?uoromethylphenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.08 (ddd, 1:243, 12.9, 
3.9 HZ, 2H), 1.35 (ddt, 1:261, 12.9, 3.9 HZ, 1H), 1.61-1.78 
(m, 6H), 1.82 (ddd, 1:132, 6.3, 3.0 HZ, 1H), 2.52 (m, 2H), 
2.71 (1, 1:81 HZ, 4H), 7.34-7.58 (m, 8H) ppm; 13c NMR 
(75 MHZ, CDC13) 6 24.9, 32.5, 32.9, 39.1, 56.7, q (118.961, 
122.560, 126.174, 129.773), q (122.757, 122.803, 122.848, 
122.909), q (125.081, 125.126, 125.187, 125.233), 128.9, q 
(130.138, 130.563, 130.988, 131.398), 131.8, 143.3 ppm. 
Compound 45: N-methyl-2,6-cis-di-(m-tri?uorom 
ethylphenethyDpiperidine 
1H NMR (300 MHZ, CDC13) 6 1.39-1.57 (m, 5H), 1.67 
(m, 2H), 1.74-1.96 (m, 3H), 2.17 (s, 3H), 2.42 (m, 2H), 2.75 
(1, 1:84 HZ, 4H), 7.36-7.50 (m, 8H) ppm; 13C NMR (75 
MHZ, CDC13) 6 25.4, 26.4, 29.7, 32.2, 36.2, 62.1, q 
(122.575, 122.621, 122.666, 122.727), q (125.233, 125.293, 
125.339, 125.384), 126.2, 128.8, q (130.001, 130.411, 
130.836, 131.261), 132.0, 143.8 ppm. 
Compound 46: 
2,6-cis-di-(p-pheny1phenethy1)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.11 (ddd, 1:237, 12.6, 
3.3 HZ, 2H), 1.34 (ddt, 1:261, 12.6, 3.3 HZ, 1H), 1.58-1.88 
(m, 7H), 2.54 (m, 2H), 2.68 (1, 1:78 HZ, 4H), 7.22-7.59 (m, 
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18H) ppm; 13C NMR (75 MHZ, CDCl3) 6 25.0, 32.3, 32.9, 
39.1, 56.9, 127.0, 127.1, 127.2, 128.8, 128.9, 138.8, 141.1, 
141.4 ppm. 
Compound 47: 
N-methyl-2,6-cis-di-(p-phenylphenethyl)piperidine 
13H NMR (300 MHZ, CDC13) 6 1.32-1.47 (m, 4H), 
1.64-1.95 (m, 6H), 2.21 (s, 3H), 2.42 (m, 2H), 2.62-2.80 (m, 
4H), 7.26-7.60 (m, 18H) ppm; 13C NMR (75 MHZ, CDC13) 
6 25.3, 26.9, 30.7, 32.0, 36.4, 62.6, 126.9, 127.2, 127.3, 
128.9, 129.0, 138.8, 141.3, 142.3 ppm. 
Compound 48: 
2,6-cis-di-(p-hydroxymethylphenethyl)piperidine 
1H NMR (300 MHZ, CDCl3) 6 1.26-1.46 (m, 3H), 1.64 
1.85 (m, 3H), 1.85-2.06 (m, 4H), 2.41-2.66 (m, 4H), 2.92 
(hrs, 2H), 6.69 (dt, 1:87, 2.5 HZ, 4H), 6.99 (dt, 1:87, 2.4 
HZ, 4H), 8.64 (m, 2H), 9.23 (s, 2H); 13C NMR (75 MHZ, 
CDCl3) 6 21.9, 27.4, 29.7, 34.8, 56.3, 115.0, 128.8, 130.6, 
155.3 ppm. 
Compound 49: 
2,6-cis-di-(p-acetoxymethylphenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.07 (ddd, 1:234, 12.6, 
3.6 HZ, 2H), 1.33 (ddt, 1:258, 12.9, 3.6 HZ, 1H), 1.80 (ddd, 
1:102, 5.7, 3.0 HZ, 1H), 2.28 (s, 6H), 2.51 (m, 2H), 2.64 (1, 
1:78 HZ, 4H), 6.99 (dt, 1:90, 2.4 HZ, 4H), 7.18 (dt, 1:90, 
2.4 HZ, 4H); 13C NMR (75 MHZ, CDC13) 6 21.4, 24.9, 32.0, 
32.8, 39.2, 56.8, 121.5, 129.3, 139.9, 148.8, 169.7 ppm. 
Compound 50: 
2, 6-cis-di-(2,4-dichlorophenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.09 (ddd, 1:240, 12.6, 
3.6 HZ, 2H), 1.35 (ddt, 1:261, 12.9, 3.6 HZ, 1H), 1.56-1.77 
(m, 6H), 1.83 (ddd, 1:132, 6.6, 3.3 HZ, 1H), 2.53 (m, 2H), 
2.74 (dd, 1:107, 7.2 HZ, 4H), 7.15 (s, 2H), 7.16 (d, 1:18 
HZ, 2H), 7.35 (dd, 1:18, 0.6 HZ, 2H); 13C NMR (75 MHZ, 
CDC13) 6 24.9, 29.8, 32.7, 37.5, 56.8, 127.2, 129.3, 129.4, 
131.1, 132.2, 134.6, 138.5 ppm. 
Compound 51: N-methyl-2,6-cis-di-(2,4-dichlo 
rophenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.30-1.56 (m, 8H), 1.65 
(m, 6H), 1.71-1.86 (m, 3 11), 2.18 (s, 3H), 2.38 (m, 2H), 
2.66-2.84 (m, 4H), 7.14-7.22 (m, 4H), 7.35 (dd, 1:18, 0.6 
HZ, 2H); 13C NMR (75 MHZ, CDC13) 6 25.3, 26.9, 29.8, 
30.6, 34.4, 62.5, 127.1, 129.3, 131.4, 132.1, 134.6, 139.1 
Compound 52: 
2,6-cis-di-(1-naphthalenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.16 (ddd, 1:234, 13.2, 
3.3 HZ, 2H), 1.39 (ddt, 1:264, 13.2, 3.3 HZ, 1H), 1.72-1.92 
(m, 7H), 2.63 (m, 2H), 3.09 (dd, 1:90, 6.3 HZ, 4H), 
7.29-7.42 (m, 4H), 7.42-7.53 (m, 4H), 7.70 (d, 1:78 HZ, 
2H), 7.84 (dd, 1:72, 2.4 HZ, 2H), 8.04 (d, 1:75 HZ, 2H); 
3c NMR (75 MHZ, CDC13) 6 25.1, 29.9, 32.9, 38.6, 57.4, 
124.0, 125.6, 125.7, 125.9, 126.0, 126.7, 128.9, 131.9, 
134.0, 138.5 ppm. 
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Compound 53: 
N-methyl-2,6-cis-di-(1 -naphthalenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.40-1.64 (m, 4H), 1.68 
1.90 (m, 4H), 2.03 (m, 2H), 2.24 (s, 3H), 2.61 (m, 2H), 3.18 
(1, 1:81 HZ, 4H), 7.34-7.41 (m, 4H), 7.42-7.54 (m, 4H), 
7.71 (dd, 1:63, 2.7 HZ, 2H), 7.85 (dd, 1:75, 1.5 HZ, 2H), 
8.11 (d, 1:81 HZ, 2H); 13C NMR (75 MHZ, CDC13) 6 25.3, 
26.7, 29.6, 30.5, 35.8, 63.1, 124.0, 125.5, 125.7, 125.9, 
126.1, 126.6, 128.9, 132.0, 134.0, 139.1 ppm. 
Compound 54: 
2,6-cis-di-(2-naphthalenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.12 (ddd, 1:237, 12.9, 
3.0 HZ, 2H), 1.39 (ddt, 1:258, 12.9, 3.6 HZ, 1H), 1.60-1.86 
(m, 7H), 2.52 (m, 2H), 2.77 (1, 1:78 HZ, 4H), 7.30 (dd, 
1:87, 1.2 HZ, 2H), 7.36-7.47 (m, 4H), 7.58 (hrs, 2H), 
7.71-7.82 (m, 6H); 13C NMR )75 MHZ, CDC13) 6 25.0, 32.8, 
32.9, 39.0, 56.9, 125.2, 126.0, 126.4, 127.4, 127.5, 127.7, 
128.0, 132.1, 133.7, 139.8 ppm. 
Compound 55: 
N-methyl-2,6-cis-di-(2-naphthalenethyl)piperidine 
1H NMR (300 MHZ, CDC13) 6 1.33-1.45 (m, 4H), 1.70 
1.83 (m, 4H), 2.02 (m, 2H), 2.23 (s, 3H), 2.48 (m, 2H), 2.85 
(m, 4H), 7.35 (dd, J:6.6, 1.5 HZ, 2H), 7.38-7.46 (m, 4H), 
7.65 (hrs, 2H), 7.74-7.82 (m, 6H) ppm; 13c NMR (75 MHZ, 
CDC13) 6 25.2, 29.7, 30.1, 32.9, 36.5, 64.1, 125.9, 126.1, 
126.5, 127.6, 127.7, 127.8, 128.2, 131.9, 133.6, 139.7 ppm. 
EXAMPLE 19 
Preparation of Compounds 56 and 57 
Compound 56 and 57 Were prepared as illustrated in 
Scheme 2 by the similar procedure as described in Scheme 
1 above. 
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Compound 56 
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extracted With ethylacetate (3><100 mL). The combined 
-continued organic layers Were Washed With brine (100 mL), dried over 
$H3 Na2SO4, ?ltered, and concentrated. The crude product Was 
N puri?ed by column chromatography (10:1 hexanes:ethylac 
5 etate) on silica gel to a White solid, yield: 76%. 
w‘ ,1’, Phenylethylmagnesium bromide (1M in THF, 25 mL) Was 
‘“\ N I," added to a solution of CuBr.SMe2 (5.14 g, 25 mmol) in 50 
AH, mL THF at —250 C. The resulting mixture Was stirred at —200 
10 C. to —300 C. for 15 min, and then cooled to —780 C. To the 
mixture Was added boron tri?uoride etherate (1.27 mL, 10 
mmol). After 30 min, above product White solid (3.73 g, 10 
Compound 561 2,6—ois-diphonothylpiporazino mmol) in 30 mL THF Was added dropWise to the mixture. 
Compound 57 
15 The mixture Was stirred at —780 C. for 3 h and then poured 
into aqueous 20% NH4Cl/NH4OH (50:50) solution (400 
mL). The aqueous layer Was extracted With ethylacetate 
lHNMR (300 MHZ, DMSO-d6) 6 7.14-7.40 (m, 10H), 
3.36-3.72 (m, 4H), 3.14 (r, 1:123 HZ, 2H), 2.62-2.85 (m, 
4H), 2.13 (m, 2H), 1.96 (m, 2H) ppm; 13CNMR(75 MHZ, 
6 Combined Organic layers Were Washed 
1402 PPHL 20 With brine (100 mL), dried over Na2SO4, ?ltered, and 
concentrated. The crude product Was puri?ed by column 
Compound 57: 
1’4_dimethy1_2’6_Cis_diphenethylpiperazine chromatography (6:1 hexanes:ethylacetate) on silica gel to 
give Troc protected compound 58 (3.09 g, 64.5%) and 59 
lHNMR (300 MHZ, CDCl3) 6 7.13-7.39 (m, 10H), 2.55- 25 (530 mg, 11%) as White solids. These compounds Were 
2.83 (In, 6H), 2.40 (In, 2H), 2.30 (S, 3H), 2.25 (S, 3H), 2.01 deprotected under Zn/HOAc at room temperature for 4 h to 
(t, 1:114 HZ, 2H), 1-93 (In, 2H), 1~70 (In, 2H) PPm; give the title compound 58 and 59, respectively. 
l3CNMR (75 MHZ, CDCl3) 6 32.2, 33.8, 35.7, 46.3, 58.9, 
61.9, 125.9, 128.3, 128.4, 142.3 ppm. Compound 58. 
30 2,6-cis—2-phenethynyl-6-phenethylperidin-4-one 
EXAMPLE 20 
1H NMR (300 MHZ, CDCl3) 6 1.76-1.98 (m, 2H), 2.18 
Preparation of Compounds 58 and 59: 2.6-ois-2- (dd, 1:138, 12.0 HZ, 1H), 2.46 (ddd, 1:138, 27, 1.8 HZ, 
phonethynyl-6-phonethylporidin-4—ono and 2,6- 35 1H), 2.54-2.78 (m, 4H), 2.87 (m, 1H), 3.90 (dd, 1:117, 4.2 
trans—2-phenethynyl-6-phenethylperidin-4-one HZ, 1H), 7.05-7.50 (m, 10H) ppm; MS m/Z 302 (M+—1). 
OMe O O O 
\ 
—> I —> 
N/ N III/II \ \\‘\\\ N '11,,’ \ I,” N " 
Troc Troc Troc 
O 0 
Compound 58 Compound 59 
TrocCl (9.26 g, 43.71 mmol) Was added dropWise at —300 Compound 591 
C. to a solution of 4-methoxypyridine (4.77 g, 43.71 mmol) 60 2a6'trans'2'phenethynyl'6'Phenethylperidin-4-0ne 
in 60 mL THF. The resulting mixture Was stirred for 30 min 1H NMR (300 MHZ, CDC13) 5 175.195 (m, 2H)’ 222 
at —300 C., and Phenylethynylmagnesium bromide (1M in (dd, 1:141, 11.1 HZ, 1H), 2.52 (ddt, 1:219, 14.1, 2.4 HZ, 
THF, 65 mL) Was added througha syringe. The mixture Was 2H)’ 271 (B 1:78 HZ: 2H} 2-79 (dd: 1:141: 6-3 HZ, 1H), 
stirred at —200 C. for 2 hours. 1M HCl (50 mL) Was then 65 5] 
added, and the mixture Was st1rred at room temperature for 470, 485’ 517, 864, 8&1, 1225’ 1262’ 1283’ 12849’ 
30 min and diluted With Water (150 mL). The mixture Was 12853, 128], 1319, 1413, 206,8 ppm; MS m/Z 303 (M+), 
US 7,368,443 B2 
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EXAMPLE 21 
High Af?nity [3H]Nicotine Binding Assay 
The ability to displace S(—)[3H]nicotine (NIC) binding 
from rat striatal membranes to assess interaction With the 
(>t4[32* subtype Was determined. The [3H]NIC binding assay 
Was performed according to previously published methods 
(Romano et al., 1980; Marks et al., 1986; Crooks et al., 
1995). Striata from tWo rats Were dissected, pooled and 
homogenized With a Tekmar polytron in 10 vol of ice-cold 
modi?ed Krebs-HEPES buffer (in mM; 20 HEPES, 118 
NaCl, 4.8 KCl, 2.5 CaCl2, 1.2 MgSO4, adjusted to pH to 
7.5). The homogenate Was incubated at 37° C. for 5 minutes 
to promote hydrolysis of endogenous acetylcholine, and 
centrifuged at 15,000 g for 20 minutes and the pellet Was 
resuspended in 10 vol of ice-cold distilled Water and incu 
bated at 37° C. for 5 minutes, folloWed by centrifugation at 
15,000 g for 20 min. The pellet containing the striatal 
membranes Was resuspended in 10 vol of fresh ice-cold 10% 
Krebs-HEPES buffer and incubated at 37° C. for 10 min 
after Which it Was centrifuged at 15,000 g for 20 minutes. 
The latter sequence of resuspension, incubation and cen 
trifugation Was repeated. The pellet Was froZen under fresh 
Krebs-HEPES buffer and stored at —40° C. until assay. Upon 
assay, the pellet Was resuspended in Krebs-HEPES bulfer, 
incubated at 37° C. for 5 minutes and centrifuged at 15,000 
g for 20 minutes. The ?nal pellet Was resuspended in 3.6 ml 
ice-cold Water Which provides for approximately 200 pg 
protein/100 pl aliquot. Competition assays Were performed 
in duplicate in a ?nal volume of 200 pl Krebs-HEPES buffer 
containing 250 mM Tris buffer (pH 7.5 at 4° C.). Reactions 
Were initiated by addition of 100 pl of membrane suspension 
to 3 nM [3H]NIC (50 pl) and 1 of at least 9 concentrations 
of analog (50 pl). After 90 minutes incubation at 4° C., 
reactions Were terminated by dilution of the samples With 3 
ml of ice-cold bulfer folloWed immediately by ?ltration 
through a Whatman GF/B glass ?ber ?lters (presoaked in 
0.5% polyethyleneimine (PEI) using a Brandel Cell Har 
vester. Filters Were rinsed 3>< With 3 ml of ice-cold bulfer, 
transferred to scintillation vials and 5 ml scintillation cock 
tail added. Nonspeci?c binding Was de?ned as binding in the 
presence of 10 pM NIC. For competition curves, the lC5O 
values Were corrected for ligand concentration (Cheng and 
Prusolf, 1973). 
EXAMPLE 22 
[3H]Dopamine ([3H]DA) Uptake Assay, Striatal 
Synaptosomal Preparation 
[3H]DA uptake Was performed according to a modi?ca 
tion of the previously reported methods (DWoskin et al., 
1999). Striata Were homogeniZed in 20 ml of ice-cold 
sucrose solution (0.32 M sucrose and 5 mM sodium bicar 
bonate, pH 7.4) With 12 passes of a te?on-pestle homog 
eniZer (clearance approximately 0.003 in). The homogenate 
Was centrifuged at 2,000 g, 4° C. for 10 min. The supernatant 
Was centrifuged at 12,000 g, 4° C. for 20 minutes. The 
resulting pellet Was resuspended in 1.5 ml ice-cold assay 
buffer (in mM; 125 NaCl, 5 KCl, 1.5 KH2PO4, 1.5 MgSO4, 
1.25 CaCl2, 10 glucose, 0.1 L-ascorbate, 25 HEPES, 0.1 
EDTA and 0.1 pargyline; pH 7.4). The ?nal protein concen 
tration Was 400 Hg/ml. Assays Were performed in duplicate 
in a total vol of 500 pl. Aliquots (50 pl synaptosomal 
suspension containing 20 pg of protein) Were added to assay 
tubes containing 350 pl buffer and 50 pl of 1 of 9 concen 
20 
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38 
trations (?nal concentration, 1 nM-1 mM) of analog or 
vehicle. Synaptosomes Were preincubated at 34° C. for 10 
min before the addition of 50 pl of [3H] DA (30.1 Ci/mmole, 
?nal concentration 100 nM) and accumulation proceeded for 
10 min at 34° C. High af?nity uptake Was de?ned as the 
difference betWeen accumulation in the absence and pres 
ence of 10 pM GBR 12935. Preliminary studies demon 
strated that at 10 minutes [3H]DA uptake is Within the linear 
range of the time-response curve When experiments are 
performed at 34° C. Accumulation Was terminated by addi 
tion of 3 ml ice-cold assay buffer containing 1 mM pyro 
catechol and rapid ?ltration through a Whatman GF/ B glass 
?ber ?lter paper (presoaked with buffer containing 1 mM 
pyrocatecol) using a Brandel Cell Harvester. The ?lters Were 
Washed 3 times With 3 ml of 10 ml ice-cold buffer containing 
2 mM pyrocatechol, and then transferred to scintillation 
vials and radioactivity determined (Packard Model 
B1600TR scintillation counter, Meriden, Conn.). Protein 
concentration Was determined using bovine serum albumin 
as the standard (Bradford, 1976). Competition curves for 
analog inhibition of [3H]DA uptake Were generated. Non 
linear regression analysis Was used to ?t curves either in the 
absence or presence of 9 concentrations of analog. lC50 
values Were corrected for concentration of [3H]DA (Cheng 
and Prusolf, 1973) to yield true inhibition constants 
(Ki:lC50/[1+c/Km]), Where c is the concentration of free 
[3H]DA and Km is the concentration of analog at Which half 
maximal [3H]DA uptake is achieved. These values (Ki) Were 
converted to pKi before statistical analysis. 
EXAMPLE 23 
[3H]Methyllycaconitine ([3H]MLA)Binding Assay 
Whole rat brain (minus cortex, striatum and cerebellum) 
Was homogeniZed in 20 vol of ice-cold hypotonic buffer (2 
mM HEPES, 14.4 mM NaCl, 0.15 mM KCl, 0.2 mM CaCl2 
and 0.1 mM MgSO4, pH 7.5). Homogenates Were incubated 
at 37° C. for 10 min and centrifuged at 25,000 g for 15 min 
at 4° C. Pellets Were Washed 3 times by resuspension in 20 
vol of the same buffer and centrifugation using the above 
parameters. Final pellets Were resuspended in incubation 
buffer to provide ~150 pg protein/100 pL. Binding assays 
Were performed in duplicate, in a ?nal vol of 250 pL 
incubation buffer, containing 20 mM HEPES, 144 mM 
NaCl, 1.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4 and 0.05% 
BSA, pH 7.5. Assays Were initiated by the addition of 100 
pL membrane suspension to 150 pL of sample containing 2.5 
nM [3H]MLA([10t, 4(S), 6B, 140t, 16[3]-20-ethyl-1,6,14,16 
tetramethoxy-4 [[[2-(-[3 -3 H] -methyl-2, 5-dioxo-1 -pyrrolidi 
nyl)benZoyl]oxy]methyl]aconitane-7,8-diol; speci?c activ 
ity 26.2 Ci/mMol) and at least 6 concentrations (30 nM-100 
pM) synthetic analog (?nal concentrations), and incubated 
for 2 h at room temperature. Nonspeci?c binding Was 
determined in the presence of 10 pM MLA. Assays Were 
terminated by dilution of samples With 3 mL ice-cold 
incubation buffer folloWed by immediate ?ltration through 
Schleicher & Schuell #32 glass ?ber ?lters (Keene, NH; 
presoaked With 0.5% PEI) using the cell harvester. Filters 
Were rinsed 3 times With 3 mL of ice-cold bulfer, transferred 
to scintillation vials, 4 mL of scintillation cocktail added, 
and bound radiolabel determined by liquid scintillation 
spectroscopy. Protein Was measured using the Bradford 
dye-binding method (Bradford, 1976) With BSA as the 
standard. 




